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ABSTRACT OF DISSERTATION 
 
 
 
THE FUNCTIONAL ROLE OF RNA BINDING PROTEIN RBMS3 AS A TUMOR 
PROMOTER IN TRIPLE-NEGATIVE BREAST CANCER CELLS 
 
 
RBMS3 belongs to the family of c-myc gene single-strand binding proteins (MSSPs) 
that play important roles in transcriptional regulation. Here, we show that RBMS3 
functions as a tumor promoter in triple-negative breast cancer (TNBC), a highly aggressive 
BC subtype. Analysis of RBMS3 expression shows that RBMS3 is upregulated at both 
mRNA and protein levels in TNBC cells. Functionally, overexpression of RBMS3 
increases cell migration, invasion and cancer stem cell (CSC) behaviors. Moreover, 
RBMS3 induces expression of epithelial-mesenchymal transition (EMT) and CSC markers. 
Conversely, loss of RBMS3 in TNBC BT549 cells inhibits cell proliferation, migration and 
mesenchymal phenotype. Correlation analysis shows RBMS3 is associated with TGF-β 
signaling. Mechanistically, RBMS3 interacts with Smad2, Smad3 and Smad4 mRNA and 
regulates the stability of these transcripts. Importantly, RBMS3 prevents TGF-β-induced 
cytostasis and apoptosis in premalignant cancer cells. Moreover, RBMS3 inversely 
correlates with expression of ESRPs, epithelial-specific splicing regulatory proteins that 
regulate morphogenesis-associated alternative splicing events. ESRPs suppress EMT 
through distinct mechanisms: ESRP1 restricted cell migration, whereas ESRP2 prevented 
cell growth. RBMS3 significantly facilitates the EMT process when ESRPs are lost. 
Collectively, the studies within this dissertation identify RBMS3 as a positive regulator of 
EMT and breast cancer progression by regulating the TGF-β signaling pathway.  
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CHAPTER 1. INTRODUCTION 
1.1 Mammary Epithelium 
About 80% of all breast cancer (BC) are invasive ductal carcinoma. Mammary 
epithelial is primarily comprised of two cell types: luminal and basal. The 
luminal/epithelial cells constitute the inner layer of the ducts and lobuloalveolar units, 
whereas the basal/myoepithelial cells form the outer basal layer. The epithelial duct is 
enveloped by a layer of basement membrane (BM), a specialized form of extracellular 
matrix rich in collagen IV and laminin. BM contains a repertoire of membrane-tethered 
growth factors that can be released by tumor cell-secreted proteases. BM also participate 
in signal transduction events via integrin-mediated cell-matrix adhesion, leading to 
alterations in cell polarity, invasiveness, proliferation and survival.  It is embedded within 
a complex stroma, which contains fibroblasts, adipocytes, blood vessels, nerves and 
various immune cells [1]. It is well documented that luminal epithelial cells establish 
apical-basal polarity during differentiation process. While the apical side is exposed to the 
lumen, the lateral surface is intimately associated with adjacent cells and basal cells 
through cell-cell contact structures, i.e. tight junctions, adherens junctions and desmosomes 
This organization is crucial for the structural integrity of the epithelia [2].  
 
           
Figure 1.1 Schematic on the main components of mammary duct  
Activation of the EMT program in non-metastatic epithelial breast tumors confers 
mesenchymal phenotypes and cancer stem cell traits to cancer cells. 
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1.2 Breast Cancer 
Statistics 
Breast cancer (BC) is the leading cause of cancer-related deaths among women [3]. 
Approximately 268670 new cases of invasive BC and 41,400 deaths are projected to occur 
for the year 2018; this mortality is primarily due to metastasis to other organs, 
preferentially the lungs and bones [4, 5]. According to American Cancer Society, there 
will be an estimate of 25,990 new cases and 10,590 deaths in Kentucky during the year of 
2018 [6]. Although the number of breast cancer cases has increased over time, breast 
cancer incidence rates have been fairly stable for the past 10 years. Early diagnosis of the 
disease can lead to a good prognosis and a high 5-year survival rate of up to 90% [7]. 
Risk Factors 
Numerous risk factors are associated with breast cancer, including gender, aging, 
family history, gene mutations, ethnicity, estrogen receptor (ER) status and unhealthy 
lifestyle [7]. Unsurprisingly, breast cancer cases are 100 times more prevalent in women 
than in men. While most breast cancers are found in women who are 50 years old or older, 
about 11% of all new cases of breast cancer in the United States occur in women younger 
than 45 years of age. About 15% of breast cancer patients have family history. The risk of 
getting breast cancer nearly doubles if a woman has a first-degree relative (mother, sister 
or daughter) who has been diagnosed with breast cancer. 5-10% of breast cancers can be 
linked to gene mutations, such as BRCA1 and BRCA2 gene mutations, inherited from one’s 
mother or father. For instance, women with a BRCA1 mutation have a 55-65% lifetime 
risk of developing breast cancer. About 85% of breast cancer occur in women without 
family history, due to genetic mutations that happen as a result of the aging process and 
lifestyle in general, rather than inherited mutations. Female breast cancer incidence and 
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mortality rates vary significantly by ethnicity in the United States. Non-Hispanic white 
(NHW) and Non-Hispanic black (NHB) women have higher incidence and death rates than 
women of other ethnicities [6]. While NHW women develop breast cancer slightly more 
than NHB women, however, NHB women tend to die of breast cancer more often, possibly 
due to the preference for developing a more aggressive type of tumor. NHW women have 
the highest rates of ER+ breast cancer, whereas NHB women have highest rates of ER- 
breast cancer [8]. According to Johns Hopkins Medicine Health Library, lifestyle-related 
risk factors for breast cancer include physical inactivity, poor diet, obesity, frequent 
alcohol consumption, breast irradiation, no or late pregnancy (after age 30), early 
menstrual periods (before age 12), late menopause (after age 55), recent use of oral 
contraceptives, long-term use of combined hormone replacement therapy and exposure to 
pesticides or other chemicals.  
Molecular Classification 
Based on molecular classifications, breast cancer can be divided into at least five 
intrinsic subtypes: HER2-enriched, luminal A, luminal B, basal-like and normal breast-like 
[9]. HER2-enrich subtype is characterized by overexpression of the HER2 oncogene and 
other genes pertaining to the HER2 amplicon. Luminal class comprises the majority of 
breast cancer and is further stratified into two subtypes. Luminal A subtype is defined as 
ER+, PR ≥20%, HER2-, Ki67 <14%, and, if available, ‘low’ recurrence risk. Luminal B 
subtype is ER+, HER2-, and at least one of the following: Ki67 ≥20%, PR- or <20%, and, 
if available, ‘high’ recurrence risk [10]. Luminal B tumors are associated with worse 
prognosis than that of the luminal A subtype. Generally, the luminal class is characterized 
by high proliferation rates, with ER expression, and/or HER expression and low /absent 
PR expression. The basal-like subtype is largely defined by lack of expression of ER and 
HER2, positive expression of genes characteristic of basal-like cells of the breast and high 
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proliferation index. Normal breast-like subtype displays a triple-negative phenotype (ER-, 
HER2- and PR-) and an expression profile similar to those found in normal breast tissue 
[11]. 
1.3 Basal-like Breast Cancer vs. Triple-Negative Breast Cancer 
Basal-like breast cancer (BLBC) is a highly malignant subtype of breast cancer. A 
large subset of this subtype is characterized by lost expression of ER, HER2 and PR and 
high expression of several basal markers, including cytokeratins (5/6, 14 and 17), EGFR, 
caveolin 1 and P-cadherin, exhibiting a ‘triple-negative’ phenotype [12]. Triple-negativity 
renders this subset of patients less responsive to hormone therapies. Undoubtedly, 
tremendous scientific advancements have been made to increase survival rates of BC 
patients, however, this is only applicable to BC diagnosed early stages without metastasis.  
BLBC accounts for up to 20% of all human breast carcinoma. While approximately 
70% of BLBC are TNBC, about 75-80% of TNBC are BLBC. BLBC with ‘triple-negative’ 
phenotype (TNBC) tend to be aggressive and destructive as it is associated with a high 
proliferation index, ensuing brain and lung metastasis, and poor clinical outcome in spite 
of treatment [13]. Compared to other molecular subtypes, BLBC still carry the worst 
prognosis due to decreased disease-free survival, disease-specific survival and overall 
survival. In addition, BLBC patients are at increased risk for early relapse or recurrence 
within 3-5 years of diagnosis. Owing to its aggressive phenotype and poor prognosis as 
well as limited response to endocrine therapy, effective treatment for BLBC has been an 
extremely difficult challenge for breast cancer researchers and clinicians worldwide [14]. 
1.4 Therapeutics 
Traditionally, aggressive breast cancers have been treated with general 
chemotherapy drugs anthracycline and paclitaxel. While being more sensitive to this 
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regimen in comparison to luminal and normal-like subtypes, over 50% of the BLBC 
patients continues to have residual disease and carry a high risk of relapse within 5 years 
of diagnosis. Besides, general chemotherapy is limited by nonspecific cytotoxicity, which 
poses significant health concerns to patients [14]. Unlike other subtypes, BLBC lacks 
expression of molecular targets that responsiveness to effective hormone therapies [15]. 
Hence, research and clinical trials for targeted therapies are being carried out in the hope 
of achieving better therapeutic indices.  
DNA repair pathway: BRCA1 mutation has been identified in 15-20% of women 
with a family history of breast cancer[16]. BRCA1 deficiency is commonly observed in 
BLBC, which provides great opportunity to targeted therapy. BRCA is responsible for 
homologous recombination repair of double-strand breaks. Platinum-based chemotherapy 
(including cisplatin and carboplatin) induces DNA cross-linking, resulting in double-strand 
breaks in cells. Cancer cells with BRCA deficiency become vulnerable to apoptosis upon 
treatment of platinum agents. Since poly(ADP-ribose) polymerase (PARP) is involved in 
base excision repair for single-strand breaks, PARP inhibitors can be combined with 
platinum agents to create more DNA lesions that are less likely to be repaired by the DNA 
repair machinery. This cooperative approach utilizes the concept of ‘synthetic lethality’ by 
targeting complementary pathways leading to a lethal combination [14]. In 2018, 5 PARP 
inhibitors (talazoparib, nirapari, rucaparib, olaparib and veliparib) have finally become 
available for patients with BRCA-mutant metastatic breast cancer. 
 Aberrant activation of the VEGF pathway shown in BLBC has led to therapeutic 
strategies to target VEGF and its receptors, including anti-VEGF antibody (Bevacizumab), 
VEGFR inhibitor and other receptor tyrosine kinase inhibitors (Sunitinib, etc.). 
Although EGFR is upregulated in most BLBCs, the use of a dual inhibitor of EGFR 
and HER2/neu (Lapatinib) does not seem to benefit HER2- BLBC patients. Inhibitors of 
other downstream kinases, such as MEK and PI3K, are also considered for targeted 
therapies[14]. 
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Within the past ten years, considerable evidence has highlighted the importance of 
immune response in influencing the progression of TNBC. Presence of tumor-infiltrating 
lymphocytes (TILs) has been widely recognized as a prognostic factor in early-stage 
TNBC.  Also, expression of immune evasion molecules in the tumor microenvironment, 
such as programmed death-ligand 1 (PD-L1), may influence TNBC prognosis. In TNBC, 
PD-L1 expression is about 40-65% in immune cells. Most patients tested as PD-L1+ in 
immune cell tumors also had positive PD-L1 expression on tumor cells [17]. Development 
of new therapeutic agents against immune checkpoint molecules, such as anti-PD-1 and 
anti-PD-L1 monoclonal antibodies has emerged, bringing BC into immunotherapy era 
[18].  
1.5 Breast Tumor Progression and Metastasis 
Like many other tumors, breast tumors progress from an early pre-neoplastic lesion 
to the development of clinically detectable distant metastatic foci, which involves a series 
of genetic and epigenetic alterations affecting both tumor cells and the surrounding stroma. 
Just like other evolutionary processes in nature, the path toward metastatic colonization is 
not only extremely complex, but also highly inefficient. Most cells that leave a tumor fail 
to seed distant organs and often die on the path [19]. To develop metastasis, epithelial cells 
in primary tumor must invade locally and escape from the physical barriers (extracellular 
matrix and basement membrane), intravasate into the circulation (lymphatic or vascular 
system), extravasate into the parenchyma of distant tissues, survive in the foreign milieu 
and re-initiate proliferation programs to form overt metastases [20, 21]. The metastatic 
potential of individual cells within the bulk of a tumor is thought to be widely 
heterogeneous, which is influenced by various factors, such as tumor size, cell of origin 
and type of oncogenic driver mutation [22].  
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1.6 Epithelial -Mesenchymal Transition 
Overview 
During development and morphogenetic events, epithelial cells undergo a process 
called epithelial to mesenchymal transition, or EMT, the concept of which was first 
described in the 1980s [23]. During EMT, cells lose epithelial characteristics, such as 
intrinsic polarity, cell-cell contact and cell-matrix contact, but gain mesenchymal 
properties, including fibroblastoid morphology, increased proliferation and motility, 
allowing them to break through the basement membrane and invade surrounding tissues, 
even to distant organs [24]. Invasion is a critical step to progression toward a malignant 
disease. Morphologically, during the initiation of EMT basal-membrane anchored cells 
transform from a cuboidal epithelial-like cell to a spindle-shaped mesenchymal-like cells 
[25]. Meanwhile, adherens junction complexes dissemble and the actin cytoskeleton 
reorganize from an epithelial cortical alignment into actin stress fibers, which are anchored 
to focal adhesion complexes. E-cadherin, a major component of the adherens junctions, 
binds tightly to β-catenin with its cytoplasmic domain, which in turn anchors to the actin 
cytoskeleton via acting-binding proteins. Loss of E-cadherin epithelial marker from the 
basolateral membrane is associated with release of membrane-bound β-catenin to the 
cytosol and activation of the canonical Wnt pathway to regulate pluripotency factors 
Oct3/4, Sox2 and Nanog, which promotes cell growth, survival and maintenance of 
stemness [26]. Loss of E-cadherin, accompanied by induction of mesenchymal markers 
(Snail, Slug, Twist1, Zeb1/2, N-cadherin and Vimentin, etc.), represent hallmarks of EMT 
and tumor progression. These phenotypic traits appear to be the fundamental molecular 
basis for tumor initiation and expansion, metastatic capacity, tumor recurrence and therapy 
resistance [27].  
The EMT program is activated through contextual signals that cells receive from 
their neighbors. In the case of carcinoma, these signals derive primarily from the 
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fibroblasts, mesenchymal stem cells and inflammatory cells that are recruited to the stroma 
of the tumors and contribute to the formation of a tumor-promoting microenvironment [28]. 
 
 
Figure 1.2 Core signaling pathways that activate EMT  
In the context of non-neoplastic cells, several cell-intrinsic signaling pathways (TGF-β, 
WNT and NOTCH, etc.) are activated, upon binding of specific ligands, cytokine or growth 
factors to their cognate receptors, to induce EMT during embryonic development and 
wound healing. Canonical WNT pathway is activated upon binding of WNT ligands to the 
Frizzled family of membrane receptors, which leads to the release of β-catenin from the 
GSK3β-AXIN-APC complex. β-catenin enters the nucleus and binds to transcription 
factors (TF) TCF and LEF to activate genes that drive EMT. The NOTCH pathway is 
stimulated upon binding of the Delta-like or Jagged family of ligands to the NOTCH 
receptor, which triggers proteolytic cleavage and release of the active, intracellular domain 
of the NOTCH receptor (NOTCH-ICD), which translocates into the nucleus to function as 
a transcriptional co-activator. TGF-β pathway also crosstalk with PI3K-Akt pathway to 
trigger the activation of mTOR complex and NF-κB, p38 MAPK pathway and the RAS-
RAF-MEK-ERK signaling axis. Several cytokines may trigger the phosphorylation, 
dimerization and activation of JAK and signal transducer and activator of transcriptional 
proteins, which also activate transcription of EMT transcription factors [29].  Details of 
TGF-β pathways is discussed below. (Figure cited from Dongre et al.[29]) 
Classification 
EMT is classified into three types based on distinct biological settings under which 
they occur, leading to various functional consequences. Type 1 EMT occurs during 
implantation, embryo formation and organ development to generate diverse cell types that 
share common mesenchymal phenotypes. This class of EMT does not cause fibrosis or 
induces an invasive phenotype resulting in systemic spread of the cell through the 
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circulation.  Type 2 EMT responds to wound healing, tissue regeneration and organ 
fibrosis. Following injury and inflammation, this program is activated as a form of repair 
event that gives rise to fibroblasts and other related cells in order to reconstruct the tissues 
[30]. However, persistent EMT caused by chronic inflammation may ultimately lead to 
organ destruction. Type 3 EMT is found in neoplastic epithelial cells at the invasive front 
of primary tumors that undergo different extents of phenotypic conversion to invade and 
metastasize through the circulation and generate life-threatening metastatic lesions at 
distant tissues and organs. While these EMT events are involved in considerably different 
biological processes, some genetic elements and regulatory mechanisms may be similar or 
well-conserved [24].   
 
Single Cell Migration 
Single cells utilize two major modes of migration: amoeboid and mesenchymal. 
Amoeboid migration features blebbing, weak adhesions and rapid motility, whereas 
mesenchymal migration exhibits extensive stress fibers, polarization and a leader-trailer 
edge [31, 32]. Amoeboid migration primarily occurs when cells deform to pass through 
pores and fibers in the ECM, whereas mesenchymal migration is accompanied by creation 
and expansion of paths as cells degrade and remodel the surrounding matrix [33]. Besides 
using matrix metalloproteases (MMPs), cells also rely on Rho kinase, integrin and 
actomyosin to enable entry into pores via deformations to the cytoskeleton [34]. The mode 
of migration employed by a cell is partially mediated by its adhesivity to the matrix and 
the architecture, porosity, composition and mechanical properties of the ECM. For 
example, intrinsic activity of actomyosin is the key to transmitting mechanical signals from 
the ECM to the cell and generation of contractile force within the cytoskeleton that is 
transmitted to adhesion complexes to facilitate movement of cells along the matrix. While 
these adhesion complexes are essential for mesenchymal migration, they are less important 
for amoeboid migration [31, 35]. 
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Collective Migration 
EMT has traditionally been described as a binary process that involves complete 
conversion from epithelial to mesenchymal state. However, recent work points to a greater 
flexibility in this transitional process, as increasing evidence reveals that EMT may 
subsume a spectrum of intermediate or ‘hybrid’ states, which has been commonly referred 
to ‘partial EMT’ [36]. For example, migratory neural crest cells, particularly those arise in 
the Xenopus and fish embryos, migrate in a collective manner but have not undergone a 
full EMT. These cells gain migratory and invasive properties but have not lost epithelial 
properties, as they maintain a significant degree of cell-cell adhesion and cadherin 
expression that allow them to migrate together in a coordinated manner using a variety of 
modes including sheets, strands, tubes and clusters [32]. Similarly, metastatic carcinoma 
cells from spontaneously-arising tumors could have activated EMT program but never 
become entirely mesenchymal by completing this process [37].  
Overall, two main types of mechanisms exist in cancer cell invasion and 
dissemination: the first type may give rise to single cells capable of crossing basement 
membrane and invading circulation; the second type where cells migrate in a multi-cellular 
cluster by retaining cell-cell contact. While both situations have been observed in mouse 
models and clinical specimens, the mechanism underlying these differences in epithelial 
plasticity remains elusive. It appears that divergent EMT programs correlate with tumor 
subtype in several human breast carcinoma lines. Typically, in the well-differentiated 
luminal A, luminal B or normal-like BC cell lines, EMT is associated with persistent 
expression of CDH1 mRNA and re-localization of E-cadherin protein, which features a 
partial EMT program [36]. Conversely, cell lines harboring a less differentiated basal 
signature and loss of CDH1 mRNA and E-cadherin protein features a complete EMT 
program (Figure 2). Aiello et al found that partial EMT cell lines are predisposed to form 
circulating tumor cell (CTC) clusters more readily than complete EMT cell lines, consistent 
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with findings of Giampieri et al., indicating that TGF-β signaling in BC cells prompted a 
switch from collective migration to single-cell migration, potentially attributable to 
conversion from partial to complete EMT program [38]. CTC clusters showed enhanced 
metastatic potential compared to single cells, Aiello et al. speculated that tumors exhibiting 
a partial EMT phenotype might exhibit an increased metastatic rate than tumors exhibiting 
a complete EMT phenotype[36, 39-41]. Likewise, tumor cells with various degrees of 
epithelial-plasticity are prone to metastasize to different sites. Due to complexity and 
multimodality in the factors governing metastasis, the relationship between partial EMT 
and complete EMT and their respective clinical outcome remain to be defined [42]. 
 
               
Figure 1.3 An epithelial-mesenchymal spectrum exist in breast cancer  
Epithelial breast cancer cells that fail to respond to EMT-inducing signals are unable to 
undergo EMT, whereas responsive epithelial cancer cells exhibit disrupted autocrine 
signaling and transition toward mesenchymal cancer cell state. Once the transition is 
complete, these cells may maintain a stable mesenchymal phenotype by autocrine signaling 
in the absence of the EMT-inducing signals [43]. The EMT process is thought to be 
reversible and is associated with tumor-initiating potential, which peaks at partial-EMT 
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phase and diminishes as cells reach a stable mesenchymal state. Listed are some of the 
factors that preferentially reside in either cell state [44]. (EMT-TF, EMT-transcription 
factors; Figure modified from Chaffer et al. [45]) 
 
 
Figure 1.4 Schematic of differences between partial and complete EMT programs  
This figure models two types of tumor cell dissemination. Poorly-differentiated BC cells 
are prone to activate a complete EMT program by transcriptional repression of epithelial 
genes and activation of mesenchymal genes. Conversely, well-differentiated BC cells, as 
observed in most epithelial tumors, modify their epithelial phenotype through an 
alternative program involving protein internalization rather than transcription repression, 
leading to a ‘partial EMT’ phenotype. As a result, cancer cells utilize this mechanism to 
migrate as clusters in the circulation, contrasting with the single-cell migration pattern 
defined by traditional concept of ‘EMT’. (Figure modified from Aiello et al. [36]) 
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Transcriptional Regulation 
Most signaling pathways leading to EMT induction converge on the down-
regulation of E-cadherin, a critical epithelial cell adhesion molecule that serves as the 
gatekeeper of EMT [46, 47]. In most cell types, loss of functional E-cadherin results in 
decreased cell adhesion, leading to uncontrolled cell growth and metastasis.  
Molecular events of EMT are transcriptionally controlled by master regulators such 
as transcription factors Snail, Slug, ZEB1/2 and Twist1/2. In most physiological EMT 
conditions, overexpression of Snail, Slug, ZEB1/2, or Twist1/2 in epithelial cell lines 
typically induces EMT [25]. Snail and Slug initiate EMT by repressing epithelial genes 
like E-cadherin through binding to E-box DNA sequences of their carboxy-terminal zinc-
finger domain, while ZEB1/2-mediated transcriptional repression often requires additional 
recruitment of a C-terminal-binding protein (CTBP) co-repressor [48]. Twist1/2 belongs 
to the basic-helix-loop-helix (bHLH) family of transcription factors and interact with E 
boxes by its bHLH domain and repress transcription of E-cadherin in a way similar to that 
of Snail. Twist, Snail and Slug work synergistically, controlling an overlapping and distinct 
sets of genes, during tumor progression. Apart from its role as a transcriptional repressor, 
Twist also serves as a transcriptional activator by recruiting BRD4 to coordinate EMT 
induction [9]. These transcription factors also regulate genes extensively involved in 
motility, proliferation, differentiation and survival [25, 49, 50]. 
 
Post-transcriptional Regulation 
Since the discovery of ribonucleoproteins (RNP), interest in RNA biology has 
escalated rapidly. Given the intimate connection from transcription to translation in 
eukaryotic gene regulation, many studies have suggested that post-transcriptional events 
involving collections of mRNAs are tightly coordinated [51]. Post-transcriptional 
regulation of gene expression is emerging as a critical factor for many cellular and 
developmental processes. In many cases, RNA-binding proteins (RBPs) are the major 
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players by interacting with either coding or untranslated regions of mRNA [52]. RBPs are 
involved in every step of RNA metabolism in terms of post-transcriptional regulatory 
processes. The subcellular localization and level at which an (RBP) is expressed is crucial 
in determining its function. Nuclear RBPs primarily regulate nascent mRNA (pre-mRNA) 
processing events, including capping, splicing, 3’-end cleavage, polyadenylation and 
nuclear export. Cytoplasmic RBPs coordinate translation-associated events, such as 
mRNA transport, competitive or co-operative control of the translation machinery and 
regulation of mRNA stability [53]. 
1.7 Signaling Pathways that activates EMT 
TGF-β Signaling  
Transforming growth factor-β (TGF-β) is a prototypic member of a large family of 
evolutionarily-conserved cytokines that includes bone morphogenetic proteins, activins, 
growth differentiation factors, Nodal and inhibins. Virtually all human cell types are 
responsive to TGF-β, as it was evolved to regulate the expanding systems of epithelial and 
neural tissues, immune system and wound repair [54]. TGF-β play critical roles in 
embryonic development, cell differentiation, cellular homeostasis and tissue 
morphogenesis [54]. Mammals express three distinct TGF-β ligands (TGF-β 1-3) and three 
high-affinity receptors (TβR I-III). TβR-I and TβR-II both harbor Ser-Thr protein kinases 
in their cytoplasmic domains that are essential for intracellular signaling. TβR-III, the most 
abundant TGF-β receptor, lacks intrinsic enzymatic activity and modulates cellular 
responses to TGF-β by forming various TβR combination. In canonical TGF-β signaling, 
ligand binding of TGF-β to TβR-II stimulates recruitment, transphosphorylation and 
activation of  TβR-I by TβR-II.  Activated TβR-I binds and phosphorylates transcription 
factors Smad2/3, which forms complex with common transducer Smad4. The heteromeric 
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Smad2/3/4 complex accumulates in the nucleus, interact with other transcription factors 
and regulate gene expression in a cell- and context-specific manner [24, 55]. 
TGF-β also signals through several non-Smad pathways, including p38 MAPK, 
JNK MAPK, mTOR, RhoA, Ras, PI3K/Akt, PP2A/p70S6K, c-Src, 4E-BP1 and eEF1A1 
[56]. Smad4 is essential for most but not all TGF-β-regulated transcriptional responses. 
TIF1γ (transcription intermediate factor 1γ, or TRIM33) is another TGF-β signal mediator 
that interacts with receptor-activated Smad2/3 in competition with Smad4 and engages in 
TGF- β-induced erythroid differentiation [57]. Most of these noncanonical TGF-β 
signaling pathways have been established in cell culture conditions, but their relevance to 
human cancer remains to be investigated. 
 
 
                                   
Figure 1.5 Schematic of TGF-β/SMAD-induced transcriptional responses  
Activation of the pathway is initiated by binding of extracellular TGF-β ligands to the 
transmembrane TβR2 (TGF-β receptor 2), leading to recruitment and oligomerization of 
TβR1. Activated TβR1 phosphorylates intracellular mediator Smad2 or Smad3, termed 
regulatory-SMADs (R-Smads). R-Smads relay the signal to the cytoplasmic effector Co-
Smad (Smad4, etc.), which enables translocation of the R-Smad-co-Smad complex into the 
nucleus and recruitment of additional co-transcriptional activators, repressors and/or co-
factors to regulate expression of target genes. (TFs indicate Transcription Factors; ‘P’ 
indicates phosphorylation; Double wavy lines indicate DNA) 
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Figure 1.6 Overview of Smad and non-Smad arms of TGF-β signaling 
TGF-β signals through specific TGF-β Ser/Thr kinase receptors (TβR1 or TβR2). 
Activated TβR1 induces Smad2/3 phosphorylation, leading to hetero-oligomerization of p-
Smad2/3-Smad4 and translocation of the complex to the nucleus to regulate target gene 
expression. Smad7 is one of the TGF-β target genes that functions as an inhibitory Smad 
by  recruiting E3 ligase SMURF1/2 to TβR1. ARKADIA-RNF12-AXIN2 enhances TGF-
β signaling by targeting Smad7 for polyubiquitination and degradation [58, 59]. In addition, 
USP4/15 deubiquitinases can remove ubiquitin chains from TβR1 to stabilize the TβR1 
receptor. FAF1 targets TβR2 for degradation by recruiting the VCP/E3 ligase complex, 
thereby limiting excessive TGF-β response. Non-Smad signaling include several branchs: 
PI3K-Akt-mTOR pathway, ERK, p38 and JNK MAPK cascade, and pathways downstream 
of Rho-like GTPase signaling intermediates [60, 61]. Both TβR1 and TβR2 are directly 
involved inthe  activation of PI3K-Akt pathway by interacting with p85 sub-unit of PI3K 
[62]. Activation of Akt by PI3K induces mTOR, which controls translational responses.  
TGF-β-mediated activation of JNK and p38 MAPK pathway is partly mediated through 
ubiquitin ligase tumor necrosis factor receptor-associated factors 4 and 6 (TRAF4/6). TGF-
β-stimulated interaction of TRAF4 with TβR1 induces K63-polyubiquitination of TRAF4 
and, as a consequence, activation of TAK1, a MAPKKK family member.  Additionally, 
TRAF6-TβR1 interaction induces auto-ubiquitination of TRAF6 and Lys63-linked 
polyubiquitination of TAK1 [63]. Concomitant activation of TAK1 results in activation of 
its downstream target mitogen-activated protein kinase 3,4 and 6 (MKK3/4/6), leading to 
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subsequent activation of p38 MAPK and JNK.  In response to TGF-β, autophosphorylation 
of TβR1 and TβR2 triggers the recruitment of Grb2 and SOS, which activates Ras and Raf-
MEK-Erk MAPK cascade. GTPase RhoA and its  target ROCK are also induced to promote 
actin stress fiber formation and mesenchymal characteristics [64-66]. (Figure adapted from 
Feng Xie, et al. [66]) 
Under physiological settings, the anti-proliferative actions of TGF-β counteract the 
effects posed by local mitogenic stimulation. Under intense mitogenic stimulation, 
however, the TGF-β pathway triggers cytostasis or apoptosis, denpending on the intensity 
of the proliferatife signals, to offset increased cell proliferation. TGF-β prevents cell cycle 
entry into S-phase by upregulation of cyclin-dependent kinase inhibitors (such as p15 and 
p21) and suppresion of c-Myc [67]. Conversely, TGF-β-induced apoptosis include several 
Smad-dependent and –independent mechanisms depending on the cellular context. TGF-β 
preferentially drives differentiation of mesenchymal precursors towards fibroblasts [68].  
In addition, TGF-β also suppresses cell proliferation and tumor formation by blocking the 
production of paracrine factors in stromal fibroblasts and inflammatory cells [54]. 
Collectively, TGF-β prevents tumor progression by regulating not only cell proliferation, 
differentiaion and survival, but also the cellular microenvironment . 
TGF-β signaling is implicated as the primary inducer of EMT. In normal epithelial 
cells and early tumorigenic cells, TGF-β signaling inhibits uncontrolled growth by 
inducing cell cycle arrest and apoptosis. However, during advance stage of tumorigenesis, 
TGF-β ligands are frequently augmented, which may be formed by tumor cells or tumor-
associated immune and stromal cells in the microenvironment of basal-like breast tumors 
[13, 69]. Malignant cells evade TGF-β suppressive effects either through mutational 
inactivation of core compoenents of the TGF-β pathway or just by disabling the tumor 
suppresive arm of the pathway, allowing cancer cells to freely usurp the remaining TGF-β 
circuit to their advantage. Particularly, breast cancer seem to preferentially disable the 
tumor-suppressive arm of TGF-β to benefit from tumor-derived TGF-β by using its as a 
shield against antitumor immunity. Collectively, TGF-β pathway facilitates cancer 
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progression and metastasis by inducing EMT, inhibiting immunosurveillance, activating 
fibroblasts and neoangiogenesis. This dramatic conversion in TGF-β function is recognized 
as the ‘TGF-β paradox’ and its detailed molecular mechanisms have not been elucidated 
entirely. 
At the transcriptional level, TGF-β directly or indirectly activates EMT by 
upregulation of transcription factors, including Snail and EF1, leading to repression of 
epithelial marker genes (e.g. Occludins, Claudin and E-cadherin)  and concomitant 
induction of mesenchymal markers (e.g. Vimentin, Smooth Muscle Actin and N-cadherin) 
[70]. TGF-β also promotes EMT by a variety of Smad-dependent and –independent effects 
on junction complexes Smad-induced expression of HMGA2 increases expression of Snail, 
Slug and Twist. TGF-β also collaborates with other signaling pathways to activate EMT 
and maintain the mesenchymal phenotype of metastatic tumor cells [71].  
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Figure 1.7 Roles of TGF-β in cancer progression 
In normal epithelium and pre-malignant cells, TGF-β enforces cellular homeostasis and 
suppresses tumor progression directly through cell-autonomous tumor sppressive effects 
or indirectly through effects on the stroma. Malignant cells circumvent TGF-β suppressive 
effects either through mutational inactivation of core compoenents of the TGF-β pathway 
or by disabling the tumor suppresive arm of the pathway, allowing cancer cells to freely 
usurp the remaining TGF-β circuit to their advantage. Therefore, cancer cells that lose 
TGF-β tumor-suppressive resoponses utilize this machinery to initiate metastatic 
dissemination, growth factor production and immune invasion [54]. (Figure adapted from 
Joan M [54].) 
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Wnt Signaling  
Three Wnt signaling pathways (canonical pathway, Wnt-calcium pathway and 
planar cell polarity pathway) operate in response to the binding of 19 distinct Wnt ligands 
to the Frizzled family of cell surface receptors [72]. Canonical Wnt pathway triggers a 
series of signaling events that culminate in the nuclear translocation of β-catenin, acting as 
a transcription co-factor, to induce the expression of a broad range of target genes involved 
in cell proliferation, differentiation, cell fate specification and tumorigenesis [73]. Wnt-
mediated activation of the EMT program involve direct transcriptional activation of various 
EMT-TFs, including TWIST, SNAI1, SNAI2, ZEB1, CDH2 and repression of CDH1. E-
cadherin, a part of the adherens junctions complex that forms lateral connections between 
adjacent epithelial cells, is a negative regulator of the canonical Wnt pathway by 
sequestering the entire β-catenin pool at the cell membrane. In particular, inhibition of 
SFRP1, a Wnt antagonist, induces EMT-like changes in immortalized mammary epithelial 
cells TERT-HMLE and sensitizes them to TGF-β-induced EMT [74]. Additionally, TGF-
β downstream target Smad7 cooperate with β-catenin to control the expression of several 
genes associated with cell adhesion and metastasis [75, 76].  
Non-canonical Wnt signaling cascade induces EMT in a β-catenin-independent but 
PKC-dependent manner. Noncanonical ligands has been found to be upregulated in human 
epithelial cells that have completely turned into a highly mesenchymal state, compared to 
those that reside in an intermediate state [77]. 
Notch Signaling  
This pathway is primarily implicated in regulating cell fate decisions, 
differentiation and proliferation. Four isoforms of single-pass transmembrane Notch 
receptors (Notch -4) are known to bind the Delta-like or Jagged family of transmembrane 
ligands, which triggers a series of proteolytic cleavage events that lead to production of the 
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active, intracellular fragment termed NICD [78, 79]. NICD translocates to the nucleus and 
associate with binding partners and factors, leading to expression of a cohort of target 
genes. NICD contains multiple domains, the RBPJ-κ association module (RAM), Ankyrin 
repeats (ANK domain) and transcriptional activation domain (TAD). TAD domain consists 
of nuclear localization sequence (NLS) and PEST domain that regulates receptor 
degradation [80]. PEST domain is likely to play a role in E3 ubiquitin-mediated turnover 
of NICD through ubiquitin-proteasome and lysosomal pathways. Mutations in the PEST 
domain have been demonstrated to increase the half-life of Notch 1-3 and upregulation of 
Notch downstream targets in TNBC [81]. During mammary gland development, Notch 
seems to be differentially expressed between cell subtypes. While Notch1 is higher in the 
luminal cells, Notch1/3 appear to mark the luminal progenitor cells. Overexpression of 
Numb, a negative regulator of Notch signaling by ubiquitylation and degradation of NICD, 
or downregulation of Cbf-1/RBPJ- κ, increases mammary stem cell (MaSC) proliferation 
and expands the pool of basal cells. Moreover, Notch4 is involved in promoting stem cell 
renewal of mammospheres [82]. Therefore, reduced Notch signaling is crucial to propagate 
the basal cell and MaSC population [83]. Notch pathway has also been implicated in 
regulating EMT in several different types of cancer [84-91]. Embryos lacking Notch1 or 
its partner RBPJ, fail to express Snail and thereby cannot undergo endocardial EMT [88]. 
Notch activates EMT by transcriptional regulation of several EMT-TFs such as SNAI1 and 
SNAI2 [92]. Numb has been shown to abrogate Notch1-mediated EMT in TNBC [93], 
whereas the E3 ligase MDM2 contributes to Numb degradation, leading to activation of 
Notch in BC. Targeting MDM2 led to a reduction in Notch signaling in MCF7 cells [94]. 
Notch also crosstalk with TGF-β pathway to induce EMT, via interaction of Smads with 
NICD and other TFs to regulate mesenchymal fate-related genes. TGF-β also can induce 
expression of Notch ligands such as Jagged 1, which act in an autocrine fashion [88]. 
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Growth Factor Signaling  
Binding of growth factor receptors by their cognate ligands stimulates receptor 
dimerization and activation of receptor-associated tyrosine kinases (RTKs). 
Phosphorylation of these receptors enables activation of the PI3K-Akt, ERK-MAPK, p38 
MAPK and JNK pathways, promoting cell proliferation, migration and motility via 
induction of EMT [95]. Upon EGF stimulation, Stat3 binds to the promoter of TWIST in 
MCF7 cells. EGF was also shown to induce nuclear co-localization of Snail and phospho-
Smad2/3 in MDA-MB-231 cells [96, 97]. Fibroblast growth factor (FGF) has been 
implicated with the induction of EMT via MAPK and MEK-ERK pathway [98, 99]. 
Hepatocyte growth factor (HGF), the ligand of MET tyrosine kinase receptor, is a potent 
activator of EMT by upregulating Sail1 [100]. Platelet-derived growth factor (PDGF) is 
found to provide an autocrine feedback loop to maintain the neoplastic human mammary 
epithelial cells in a more mesenchymal phenotype [101].  
1.8 RNA Binding Protein 
As soon as a gene is transcribed, many post-transcriptional events are expected to 
occur before the protein product is synthesized, such as mRNA processing, 
nucleocytoplasmic export, mRNA localization, mRNA stabilization and translational 
regulation. A majority of these events are controlled through a complex network of 
RNA/protein interactions involving recognition of specific target mRNAs by RNA binding 
proteins (RBPs) [102].  Post-transcriptional regulation of gene expression results from 
spatiotemporal equilibrium and dynamics between the regulatory sequences found on the 
mRNA, RBPs as well as the signaling pathways that modify them under a particular 
cellular context. Alteration of any of these determinants may disturb the equilibrium and 
thus the expression level of a given protein, causing a broader effect to cell homeostasis. 
Deregulation of gene expression may enable the cell to re-enter cell cycle, conferring them 
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growth or motility advantage over normal cells [102]. Currently, approximately 500 RNA 
binding domains (RBDs) have been characterized in the human genome.  
While a growing body of reports published on the association of specific factors 
with a given RNA, these studies merely unveiled isolated pieces of jigsaw puzzle out of 
the entire landscape of post-transcriptional regulation. The dynamics and kinetics of the 
pivotal RBPs and their targets must be fully addressed in order to comprehend how to 
achieve a certain expression level of a given gene and how it affects oncogenesis.  
1.9 Alternative Splicing 
Overview 
Splicing is largely carried out by the main spliceosome, a complex machinery 
composed of five small nuclear ribonucleoprotein particles (U1, U2, U4, U5 and U6 
snRNP) and a large variety of auxiliary proteins [103]. Alternatively, a small number of 
introns are processed by the minor spliceosome comprised of U11, U12, U4atac/U6atac 
and U5RNPs [104]. The main spliceosome machinery recognizes short consensus 
sequences at the exon-intron junctions and catalyzes two transesterification reactions 
necessary for the inclusion of exons and removal of introns. Due to the short and degenerate 
nature of the splice sites, additional factors are often required to assist the spliceosome 
function. The activity of the spliceosome is strictly regulated by both cis-acting sequences 
on the pre-mRNA and transacting factors, which may either enhance or inhibit recognition 
of splice site and splicing reaction [105]. Two main classes of RBPs that regulate splicing 
by binding to the cis-acting elements are Ser/Arg rich (SR) proteins and the heterogeneous 
nuclear ribonucleopreoteins (hnRNPs), one exert positive regulation and another function 
as antagonistic inhibitor of splicing [106]. 
Alternative splicing adds an additional layer of complexity to the splicing process 
by the presence of exons characterized by weak element defining exon-intron boundaries. 
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Differential assortment of weak or variable exons allows a gene to produce multiple splice 
variants, encoding protein isoforms with different or even opposite function of distinct 
patterns of spatiotemporal expression [107]. The advent of high-throughput sequencing 
technologies has revealed that over 95% of human genes are estimated to undergo 
alternative splicing to expand proteome diversity by producing multiple mRNA and protein 
isoforms per gene [108]. This RNA processing event is mediated by the intricate interplay 
between splicing factors and defined RNA sequences/splice sites within the pre-mRNA. 
Pre-mRNA splicing occurs in multivariate modes, the most common of which is alternative 
inclusion of cassette exons. Other common modes include alternative 5’ or 3’ splice sites, 
intron retention, mutual exclusion of cassette exons, exon scrambling and trans-splicing. 
While tissue specificity for the dominant isoform per gene is found in more than half of all 
genes, switch-like events occur in about 35% of genes between any two tissue types [109]. 
Alternative splicing plays a pivotal role in controlling core cellular processes, such 
as proliferation, metabolism, apoptosis, physiological decisions, induction of 
differentiation and maintenance of pluripotency. Aberrant regulation of alternative splicing 
contributes to the onset or progression of several human diseases, including cancer [107].  
As documented by numerous studies, specific splice variant signatures are strongly 
associated with particular types of cancer, thus representing suitable targets for the 
development of valuable antitumor therapies. In light of this, great interest has arisen for 
the investigation of the tumorigenic vs. normal splicing patterns and the search of 
approaches to switch splicing patterns from tumoral variant toward non-tumoral isoform. 
Specifically, two possibilities have been proposed: one is to target the specific activity of 
the oncogenic splice variant, another is to target the mechanism driving the aberrant 
splicing event [107].  
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Epithelial Splicing Regulatory Proteins and EMT 
Alternative splicing must be tightly-regulated, in a spatiotemporal manner, to 
ensure the expression of functionally different splice isoforms. Changes in cellular 
phenotype, such as EMT, is modulated at the level of alternative splicing by a number of 
splicing factors. Alternative splicing was the first post-transcriptional mechanism linked to 
EMT [110]. Epithelial splicing regulatory protein (ESRP) 1 and 2 were first identified as 
specific regulators of fibroblast growth factor receptor-2 (FGFR2) splicing as well as other 
epithelial-specific variants. Cell type-specific expression of epithelial and mesenchymal 
isoforms of FGFR2 splicing occurs by inducing the switch of mutually exclusive exons 
IIIb and IIIc, respectively. Microarray analysis of PNT2 epithelial cells after ESRPs 
knockdown showed that loss of splicing program alone can induce some of the phenotypic 
changes that occur during EMT, suggesting that the ESRP-regulated splicing program is 
an essential aspect of the epithelial phenotype and many EMT-associated cellular changes 
are due to functional alterations of proteins that undergo isoform switch during this process. 
Role of Alternative Splicing in Breast Cancer 
Aberrant alternative splicing (AS) events are linked to BC onset and progression.  
Carriers of BRCA1 mutations are predisposed to breast cancer with lifetime risk of up to 
80% than non-carriers [111]. Mutation of the BRCA1 gene within specific sequences 
affects the binding of splicing factors, leading to AS events of BRCA1 and production of 
variants that lack functional domains of the protein, thus compromising its tumor 
suppressor activity [112, 113]. Similarly, point mutations may also occur in splicing 
factors, resulting in inaccurate AS of cancer-related genes, such as favoring proto-
oncogene splice variants over tumor suppressor splice variants [114]. Deregulation of 
splicing factors, and also other RBPs, can also cause repercussions on splice site selection, 
and thereby are associated with development and progression of  BC (Figure ) [112].  
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1.10 mRNA Stability and Translation 
The majority of mRNA regulatory elements involved in modulation of post-
transcriptional events are situated within the 5’ and 3’-UTR, where they act as platforms 
for the assembly of regulatory factors. While the 5’-UTR is primarily engaged in 
controlling mRNA translation, the 3’-UTR regulate multiple aspects of the mRNA 
metabolism, such as nuclear export, cytoplasmic localization, mRNA stability and 
translational efficiency [115-117].  
Tight regulation of mRNA half-life plays a pivotal role in normal cell functions. 
Substantial stability renders a mRNA available for translation for a longer time, yielding 
high levels of protein products. Differences in the length and structure of the 3’-UTR 
expands the mammalian gene products generated by AS and alternative polyadenylation 
[118, 119].  
The structure of an mRNA- 5’ untranslated region (5’-UTR), 5’ cap structure, open 
reading frame (ORF), 3’ untranslated region (3’-UTR) and 3’ terminal poly (A) tail- 
governs mRNA stability and translational efficiency. RNA sequence elements like 5’ cap 
and 3’ poly(A) tail are universally present in all mRNAs and convey constitutive processes 
without apparent selectivity of one mRNA relative to another [109]. However, numerous 
cis elements have been described which pose effects on stability and/translation of given 
subsets of mRNAs. In the 5’-UTR, the iron-response elements, JNK-response elements 
and turnover determinants are present in the chemokine ligand 1 (KC) mRNA. These 
elements dictate the activities of trans factors which elicit responses on several processes 
such as translation, turnover, storage and transport. mRNA decay elements such as CRD-
1 have been observed in the ORF of mRNAs such as c-fos, c-myc and β-tubulin. 3’-UTRs 
are well recognized to contain turnover and translation determinants that bind RBPs to 
target specific mRNA for stabilization/destabilization or translational 
activation/repression. To-date the most commonly found 3’-UTR cis element are the AU-
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rich elements (AREs), which often contain a variable number of AUUA pentamers, 
sometimes harbored within a U-rich region. AREs are found on numerous mRNAs 
encoding oncogenes, cytokines, interleukins, TNF-α and cell-cycle regulators such as c-
fos, c-myc and cyclins A, B1 and D1. Many of them are overexpressed during cellular 
transformation due to mRNA stabilization or enhance translation [102, 109]. Other specific 
secondary structures such as stem-loop motifs are found on 3’-UTR of cell cycle-regulated 
histone mRNAs [109]. Together, these regulatory elements serve as binding sites for a 
variety of RBPs that modulate mRNA stability and translation efficiency. Given the 
abovementioned involvement of these regulatory elements and trans-acting factors (e.g. 
RBPs), alterations in any of these components can cause major impact on mRNA half-life 
and/or translation, resulting in aberrant levels of expressed protein and hence metabolic 
changes leading to disease.  
Regulation of mRNA stability and translation occurs via interaction of cis elements 
with trans-acting factors, which in turn target the mRNA for rapid degradation or protect 
it from nuclease access and/or regulate translational efficiency.  
Several trans-acting factors are emerging as core regulators of expression of 
cancer-related genes. In general, the levels of RBPs are frequently elevated in cancer. Each 
RBP is likely to regulate a discrete but broad subset of target transcripts simultaneously, 
thus leading to an expanding functional network of changes which pose significant 
consequences for cancer cell biology [120]. Some of the changes occur at the level of AS, 
generating variants that promote multiple aspects of tumorigenesis, which enables cancer 
cells to rapidly adapt to adverse conditions encountered during transformation, leading to 
chemoresistance.  
Cancer genes are characterized by their altered gene expression and/or activity 
leading to abnormal phenotype. Such changes confer the cell with competitive growth 
advantages: enhanced cell division, resistance to cell death, increased angiogenesis, 
invasion and metastasis, and evasion of immunosurveillance. Apart from gene mutation, 
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additional mechanisms also contribute to abnormal level of gene products in cancers, such 
as gene dosage, gene transcription, post-transcriptional control of the mRNA and regulated 
proteolysis [109]. 
RBPs that Regulate mRNA Stability and/or Translation 
RBPs influence translational efficiency primarily through three modes of action: 
direct interaction with mRNA, bridging other RBP from its target mRNA, and tag a mRNA 
for rapid deadenylation/degradation or to protect it from nucleases [121].  
One of the best studied mRNA stabilizing protein is HuR, a ubiquitously expressed 
member of the embryonic lethal abnormal vision (ELAV) family of ribonucleoproteins. 
HuR regulates cyclin A and B1 mRNA stability in a cell cycle-dependent fashion by 
nuclear-cytoplasmic shuttling of HuR. Other members of this family, such as neuronal 
specific HuB, HuC and HuD, also participate in mRNA stabilization. HuR is well known 
of its ability to recognize AU-rich elements (AREs) found on 3’-UTR of specific mRNAs, 
which influences different cellular processes such as proliferation, differentiation, 
apoptosis, inflammation, stress response and cancer [51, 122]. Snail mRNA is one of the 
HuR targets. The binding of HuR to Snail 3’-UTR is significantly increased following 
exposure to H2O2, which triggers EMT in several cell types [123]. HuR has been reported 
to bind to p53 3’-UTR to enhance its translation [124].  
CUG triplet repeat RNA binding protein 1 (CUGBP1), or ELAV-like family 
member 1, is another example of mRNA stabilizing protein. CUGBP1 and CUGBP2 are 
members of the CELF (CUGBP and ETR3-like factors) family of RNA binding proteins. 
Upon binding to the ARE in the cyclooxygenase-II (COX-2) mRNA, CUGBP stabilizes 
COX-2 mRNA to repress its translation [102].   
Several RBPs have opposite effects on mRNA stability. AU-rich element RNA 
binding protein 1 (AUF1), or hnRNP D, consists of four isoforms of 37, 40, 42 and 45 kDa. 
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AUF1 is correlated with rapid degradation of ARE-containing mRNAs [125]. 
Tristetraprolin (TTP or ZFP36), characterized by two tandem repeat zinc finger motifs, 
binds to AREs and mediate mRNA decay [126]. Several other targets of TTP include TNF-
α, VEGF, IL-1, IL-8, GM-CSF and HIF-1 [127]. KH-type splicing regulatory protein 
(KSRP) is another example of mRNA decay protein by binding to AREs [128]. 
1.11 Introduction to RBMS3 
RNA binding motif, single-stranded interacting protein 3 (RBMS3) belongs to the 
small family of c-myc single stranded binding proteins, which contains two 
ribonucleoprotein domains (RRM).RBMS3 was initially identified as binding to an 
upstream element of the mouse collagen α2 gene promoter [129]. RBMS3 was later shown 
as a tumor suppressor by regulating G1/S progression, cell proliferation and inhibit 
angiogenesis in gastric cancer and nasopharyngeal carcinoma [130-132]. Downregulation 
of RBMS3 was also found to facilitate development and progression of lung squamous cell 
carcinoma. RBMS3 was to be expressed in activated hepatic stellate cells, a type of 
mesenchymal cells of the liver, and liver fibrosis [133]. Despite this, the effect of RBMS3 
appears to be controversial. Recent literature suggested that loss of RBMS3 confers 
chemoresistance to epithelial ovarian cancer via activation of miR-126/β-catenin/CBP 
signaling [134].  RBMS3 has been reported to function by binding to the 3’-UTR of its 
targets to increase mRNA stability and half-lives in gastric cells, activated hepatic stellate 
cells and zebrafish embryo [133, 135, 136].  
One of the best developmental function of RBMS3 is studied in zebrafish. Zebrafish 
RBMS3 was transiently expressed in the cytoplasm of condensing neural crest cells within 
the pharyngeal arches. Morphants for RBMS3 demonstrated severe craniofacial defect 
phenotype resembling cartilage/crest defects observed in Tgf- βr2:Wnt1-Cre mutants, with 
reduced proliferation of prechondrogenic crest and significantly altered expresison for 
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chondrogenic/osteogenic lineage markers. Zebrafish RBMS3 posttranscriptionally 
regulate one of the major cartilage differentiation effectors, the TGF-βr pathway, to driving 
central neural cells down to a chondrogenic lineage [136]. 
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CHAPTER 2. RATIONALE, SPECIFIC AIMS AND INNOVATION 
Rationale and Specific Aims 
     Triple-negative breast cancer (TNCB) represents up to 15-20% of all breast 
cancers and show enhanced invasiveness, metastatic potential and worse prognosis. 
Metastasis, the cause of 95% of cancer-related deaths, represents the biggest clinical 
challenge accounting for the vast majority of cancer-related deaths. However, effective 
therapeutic strategies targeting breast cancer metastasis are still scarce due to 
spatiotemporal intra-tumor cellular heterogeneity. Improved approaches to identify TNBC 
in the clinic and better understanding of the molecular programs that defines the metastatic 
potential of TNBC are urgent.  
Cancer metastasis is mediated by cellular interactions in response to signals from 
the tumor microenvironment affecting dynamic remodeling of the actin cytoskeleton 
contributing to the modulation of cell adhesion, migration and invasion. TGF-β is known 
to be highly expressed in the breast tumor microenvironment. TGF-β acts as a negative 
growth factor via growth inhibition and apoptotic induction in healthy cells and early 
tumor cells, however, it switches to promoting cell invasion, angiogenesis and cell 
adhesion and migration at later stages of tumorigenesis [137]. While the mechanism 
underlying the switch from a growth suppressor to a metastasis promoter is largely 
unknown, understanding how cancer cells interpret TGF-β signals from the 
microenvironment is necessary for elucidating the process. Previous evidence from 
zebrafish demonstrated the physical interaction between RBMS3 and Smad2/3 
transcripts, establishing the role of RBMS3 in regulating chondrogenesis by stabilizing 
the pool of Smad2/3 transcripts in order to maintain a high level of TGF-β signaling and 
thus cells remain at the mesenchymal state. Since RBMS3 is highly expressed in BLBC 
cells and its function in BC is unknown, here we propose BLBC cells exploit the same 
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mechanism to fuel the TGF-β pathway. Hence, the specific aims of the first part of my 
work are: 1) to study the function of RBMS3 in BC cell migration and invasion; 2) to 
investigate the role of RBMS3 in TGF-β signaling. 
90% of BC metastasis occurs in the mammary duct. Although metastatic BC cells 
often express basal markers, the basal/myoepithelial layer is not thought to be the source 
of metastasis, but rather a barrier for metastasis. Therefore, it becomes an enigma how the 
organized luminal cells break this entity and spread to other organs. At the 
posttranscriptional level, the identity of luminal cells is strictly governed by lineage 
determinants like the master regulator ESRP1/2 proteins. ESRPs not only organize cell 
polarity, cell migration and proliferation, but are also known to suppress the expression of 
EMT genes. Unlike the less metastatic luminal BC cells that overexpress ESRPs, metastatic 
TNBC cells express little to no ESRPs. Conversely, in our preliminary work, we found that 
TNBC cells preferentially express an RBP, RBMS3, which is absent in luminal BC cells. 
The mutually exclusive pattern of ESRPs and RBMS3 led us to speculate that RBMS3 is 
a mesenchymal lineage determinant that may be required for enhancing or maintaining 
mesenchymal phenotypes. Therefore, we hypothesize that RBMS3 is a tumor promoter in 
the TNBC cells. We also speculate that if we swap the ESRPs with RBMS3, luminal BC 
cells may lose their epithelial identity and adopt mesenchymal features. Therefore, the 
specific aims of the second part of my work are: 1) to understand the functional similarities 
and differences of ESRP1, ESRP2 and RBMS3; 2) to perform RNA-seq analysis on the 
established cells and study the posttranscriptional profiles to understand the networks 
controlled by these RBPs; and 3) to identify common targets that may be critical for BC 
cell migration, adhesion and invasion.  
Overall, my hypothesis is that RBMS3 is a tumor promoter involved in regulating 
RNA metabolism and splicing in TNBC. 
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Innovation 
The study is based on the hypothesis that RBMS3 plays tumor-promoting roles through its 
abilities to regulate RNA metabolism or splicing. The overall innovations are: 1) This is 
the first study to demonstrate the oncogenic function of RBMS3, which will provide a 
better understanding to the impact of RBMS3 on BLBCs. 2) This is also the first to 
delineate RBMS3-mediated regulation of RNA metabolism and splicing in BC. 3) This 
study proposes a novel strategy to study three RBPs by swapping ESRPs with RBMS3 in 
luminal BC cells. 
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CHAPTER 3. MATERIALS AND METHODS 
3.1 Cell Lines and Cell Culture 
          The MCF7, MDA-MB-231, MDA-MB-157 and Hs578T breast cancer cell lines 
were grown in Dulbecco’s modified Eagle’s medium (DMEM)/F12 supplemental with 10% 
fetal bovine serum (FBS), 100μg/mL streptomycin and 100 unit/mL penicillin. T47D and 
BT-549 breast cancer cell lines were grown in RPMI1640 plus 10% FBS. All cells were 
cultured at 37°C in humidified air containing 5% CO2. For establishing stable clones of 
RBMS3 knockout or overexpression, transfected cell lines were selected with puromycin 
(1 μg/mL) for 4 weeks followed by selection of single clones. 
3.2 Plasmids, Drugs, Antibodies and Primers 
          Stable RBMS3 knockout cells were generated by lentiCRISPR V2 purchased from 
Addgene. LentiCRISPR V2 vector was digested with BsmBI and ligated with indicated 
annealed oligonucleotides. Targeting sequence for RBMS3 is as the following: 
CAGCTACATGGGCAAACGCC. Stable ESRP1 and ESRP2 knockout cells were 
generated by lentiCas9-Blast purchased from Addgene. Targeting sequences for ESRP1 
and ESRP2 are CTGGACCAAGCCCTCCGA and AGTCGGTCTCGTCCGAGCC, 
respectively.  
          Anti-ESRP1 antibody (HPA023719) was from Sigma. Anti-ESRP2 antibody 
(ab155227 and ab113486) was from Abcam. Anti-RBMS3 antibody (GTX47423) was 
from Genetex. Antibodies against E-cadherin (14472), Snail (3879S), Twist (46702S), 
Slug (9585S) and Vimentin (5741T) were from Cell Signaling. Anti-Smad2/3 antibody 
was a sample from Santa Cruz. Anti-Smad2, Smad3 and Smad4 antibodies were sample 
kit from Cell Signaling. Anti-β-actin antibody (MA5-15739) was from Thermo. Anti-
Strep-Tag antibody (2-1509-001) and Strep-Tactin XT Superflow 50% suspension (2-
4010-002) were from IBA Life Science. Recombinant human TGF-β1 was purchased from 
Peprotech (100-21). A8301 (SML0788) and actinomycin D (A1410) were purchased from 
Sigma-Aldrich.  
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Table 1 Primers for qPCR 
Gene Forward Primer Reverse Primer 
SMAD2 AGCAGGAATTGAGCCACAGAGT AAGAGTAGTAGGAGATAGTTCT 
SMAD3 ACCACTACCAGAGAGTAGAGA TGGGGCTCGATGCCTGCGGGGA 
SMAD4 ACTGCCAACTTTCCCAACATT ACCAGTAAATCCATTCTGCTGCT 
SMAD7 CCCCATCACCTTAGCCGACTCTGC CCCAGGGGCCAGATAATTCGTTCC 
CTGF ACTGTCCCGGAGACAATGAC TGCTCCTAAAGCCACACCTT 
PAI1 ATTCAAGCAGCTATGGGATTCAA CTGGACGAAGATCGCGTCTG 
ID2 TCAGCCTGCATCACCAGAGA CTGCAAGGACAGGATGCTGAT 
MMP1 ATCGGGGCTTTGATGTACCC GGCTGGACAGGATTTTGGGA 
PTGS2 AGTCCCTGAGCATCTACGGT GCCTGCTTGTCTGGAACAAC 
OCT4 GGAGGAAGCTGACAACAATGAAA GGCCTGCACGAGGGTTT 
SOX2 TGCGAGCGCTGCACAT TCATGAGCGTCTTGGTTTTCC 
BMI1 TGCTGGAGAACTGGAAAGTG GATGAGGAGACTGCACTGGA 
β-Actin AGAGCTAGCTGCCTGAC GGATGCCACAGGACTCCA 
 
3.3 Cell Viability Assay 
          This assay was performed essentially described by CellTiter-Glo 2.0 Manual. Briefly, 
luminal cell lines (T47D and MCF7) were plated at a density of 20,000 cells per 96 well 
plate (in triplicate) and allowed to grow for a specific time course. At desired time point, 
add reagent equal to the volume of medium in each well. Allow mixing for 2 minutes on 
orbital shaker and another 10 minutes of incubation at room temperature to induce cell lysis 
and stabilization of signals. Luminescent signals were measured on Synergy HTX Multi-
Mode Microplate Reader.  
3.4 Transwell Migration and Invasion Assay 
          Cell were grown to 80% confluency, resuspended in serum-free medium and seeded 
into the upper chamber of Transwell inserts with an 8 μm pore size membrane (Falcon) at 
5x104 cells per insert. For the invasion assay, upper chambers of Transwell inserts were 
pre-coated with 50 μL of Matrigel (BD Biosciences), which was allowed to dry for 1 
hour prior to seeding of cells for invasion. The cells were allowed to migrate toward 
DMEM/F12 supplemented with chemoattractant epidermal growth factor (EGF) 
(20ng/mL) in the lower chamber. Basal-like MDA-MB-231 and BT-549 cell lines were 
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incubated for 8 hours for migration assay and 24 hours for invasion assay. T47D and 
MCF7 cells were incubated for 24 hours for migration assay and 48 hours for invasion 
assay. At the end of incubation period, cells remaining in the upper side of the Transwell 
insert membrane were mechanically removed using a cotton swab. The cells on the 
bottom of the Transwell insert were washed twice with PBS, fixed with 4% 
paraformaldehyde (2 minutes), methanol (10 minutes), washed once with PBS, and then 
stained with 0.5% (w/v) crystal violet in 20% methanol (v/v) (10 minutes). The stained 
cells in 4 non-overlapping fields from each insert were counted with an inverted 
microscope, using the 20X objective (Eclipse TS100, Nikon Instruments, Melville, NY). 
All experiments were performed in triplicates. 
3.5 Colony formation Assay 
          Colony formation assay was performed using double-layer soft agar in 6-well plates 
with a top layer of 0.35% agar and a bottom layer of 0.7% agar. Briefly, cells were 
suspended in 0.35% agar medium and laid on the top of the supporting agar layer (0.7% 
agar) in 6-well plates, and fed twice per week. Colonies were allowed to form in an 
incubator at 37°C and 5% CO2 for 14 days. At the end of the incubation time, cell cultures 
were photographed and the colonies were stained and counted. 
3.6 Would Healing Assay 
          Cells for scratch assay were seeded at same density on 6-cm dish. At about 90% 
confluency, cells were starved overnight. Next morning, a consistent wound (gap) was 
created using pipette tip. After removal of cell debris with PBS, cells were replaced with 
fresh medium and incubated for 24 hours. Gap measurement was performed by ImageJ 
software. Migration rates were calculated using data from 10 measurements of random gap 
points.  
3.7 Mammosphere Assay 
          Mammosphere assay was performed following the protocol previously described 
[138]. Briefly, cells were seeded in single-cell suspension in triplicates into ultra-low 
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attachment 6-well plates (Corning) in DMEM/F12 medium supplemented with 
20 ng/mL EGF, 5 mg/mL insulin, 0.5 mg/mL hydrocortisone and 2% B27. After 2 weeks 
of incubation, the presence of spheres was assessed by inverted microscopy. At least 20 
random fields for each cell lines were visualized; the number and size of spheres in the 
20 fields were calculated as a percentage over that of parent cells. 
3.8 3D On-top Matrigel Assay 
          This assay was performed following an established protocol.  Essentially, pre-chilled 
culture surface was coated with a thin layer of Matrigel. Single cell suspension was 
subjected to centrifugation at ~115 g, resuspended in half the medium volume and plated 
onto coated surface at 0.2x105 /cm2. A layer of 10% Matrigel (in medium) was added on 
top to stabilize the cells and culture was maintained for 4 days. 
3.9 Anchorage-independent Growth Assay 
          To observe the adhesion-independent growth of 14 luminal BC-derived clones, 
0.8x103 cells were seeded in 96-well round bottom ultralow-attachment plates. Cells were 
cultured for up to one week and photographs were taken daily. 
3.10 RNA Isolation and Quantitative Real-Time PCR (qPCR) 
          Total RNA was prepared using the RNeasy Mini kit (Qiagen) according to the 
manufacturer’s instructions. Specific quantitative real-time PCR experiments were 
performed using SYBR Green Power Master Mix following manufacturer’s protocol 
(Applied Biosystems). All values were normalized to the level of β-actin. 
3.11 Immunofluorescence Staining and Western Blot Analysis 
          Experiments were performed as described previously [139, 140]. For 
immunofluorescence staining, cells were grown on cover slips, fixed with 4% 
paraformaldehyde and incubated overnight with anti-Strep-Tag primary antibodies. 
Secondary antibodies were 568 goat anti-mouse IgG (H + L) (Molecular Probe, Carlsbad, 
CA). Finally, cover slips were visualized under Nikon confocal microscope.  
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          For Western blot analysis, cells were rinsed and collected on ice with cold PBS 
by scraping. After centrifugation at 1000rpm for 3 minutes and removal of PBS, cell 
pellet was lysed with lysis buffer (50mM Tris-HCl pH 7.4, 150mM NaCl, 0.2mM EDTA, 
1% Triton-X100, 10% glycerol, 5mM β-glycerophosphate, 5mM 4NPP, 1mM Na3VO4, 
5mM NaF, 2 μg/mL aprotinin, 1 μg/mL leupeptin and 0.5 tablet of protease inhibitor 
cocktail). Cells were homogenized by gentle up-and-down pipetting and lysed for 10 
minutes on ice followed by sonication for 1 minute. After high speed centrifugation for 
15 minutes, supernatants were transferred in new tubes and protein levels were 
quantified via Bradford assay followed by normalization. Sample buffer (4X) was added 
at a ratio of 1:3 and proteins were then separated by SDS-PAGE gels, transferred to 
PVDF or NC membrane and immunoblotted. 
3.12 Crosslinking RNA Immunoprecipitation (CLIP) 
          This experiment was performed based on an established protocol. Cells were grown 
on 15 cm dish and cultured to around 90% confluency. To crosslink in vivo, 37% 
formaldehyde was added directly to cells in medium dropwise to a final concentration of 
0.75% and incubated with gentle shaking for 10 minutes at room temperature. 125mM 
glycine was then added for 5 minutes. Cells were rinsed and collected on ice with cold PBS 
by scraping. After centrifuge at 1000rpm for 3 minutes, cell pellet was resuspended with 
equal volume of polysome lysis buffer (100 mM KCl, 5 mM MgCl2, 10 mM HEPES pH7.0, 
0.5% NP40, 1 mM DTT, 100 unit/mL RNase Out, 400 μM VRC, 10 μL protease inhibitor 
cocktail) by gentle up-and-down pipetting. After high speed centrifuge for 15 minutes, 
cell lysate was transferred to new tube and quantified for protein level. 20 μg lysate was 
saved as RNA input at -20 °C for later use. Meanwhile, 100 μL Strep-Tactin beads were 
washed twice with ice-cold NT2 buffer (50 mM Tris-HCl pH7.4, 150 mM NaCl, 1 mM 
MgCl2, 0.05% NP40). After final wash, beads were resuspended in 850 μL ice-cold NT2 
buffer supplemented with 200 units of RNase Out, 400 μM VRC, 1 μL of 1M DTT and 
EDTA to 20 mM. For each RIP reaction, 2 mg cell lysate was added to the beads and 
the total reaction volume was adjusted to 1 mL. Bead-lysate mixture was incubated on 
rotation for 3 hours at 4 °C. Beads were pelleted by centrifuge at 2000rpm for 3 minutes 
at 4 °C and washed four times with ice-cold NT2 buffer with rotation at 4 °C. Meanwhile, 
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previously-collected cell lysate (RNA input tube) was thawed on ice. At final wash, 1/5 
beads were collected for western blot analysis. After final wash, 1 mL Trizol reagent 
(Invitrogen) was added directly to the beads and cell lysate (RNA input tube). RNA was 
extracted following the manufacturer’s manual. 30 μg glycogen was added as a carrier 
to aid in RNA precipitation. After cDNA synthesis, quantitative real-time PCR was 
performed to determine the levels of desired transcripts. All equipment was kept at 
RNase-free level and all reagents were prepared with RNase-DNase-free H2O. 
3.13 Fluorescence-Activated Cell Sorting (FACS) 
          Cell Surface Marker Assay: Cells were detached from plates, blocked with 2% 
BSA for 30 minutes and incubated with anti-human CD24 (PE-conjugated, ebioscience), 
anti-human CD44 (PE-Cy7-conjugated, ebioscience), anti-human CD49f (PE-Cy7-
conjugated, ebioscience) or EPCAM and finally analyzed using FACSCalibur flow 
cytometer. 
          Annexin Early-Apoptosis Assay: Experiment was performed essentially as 
described by manufacture’s protocol using Annexin V-FITC Early Apoptosis Detection 
Kit (Cell Signaling Technology). Briefly, MCF7 cells stably expressed control or 
RBMS3 vector were treated with TGF-β1. 105-106 cells were detached from plates and 
resuspended with ice-cold Annexin V binding buffer. 1 μL Annexin V-FITC conjugate 
and 12.5 μL Propidium Iodide (PI) solution was added to 96 μL cell suspension. After 
10 minutes of incubation on ice in the dark, cell suspension was diluted to a final volume 
of 250 μl/assay with ice-cold Annexin V binding buffer. Analysis was performed 
immediately using FACSCalibur flow cytometer.  
          Cell cycle analysis: The experiment was performed essentially as previously 
described [141]. Briefly, cells were seeded and treated with TGF-β1 for 24 hours. Cells 
were harvested and fixed in cold 70% ethanol at -20 °C for overnight. Cells were washed 
with phosphate buffered saline (PBS) twice and stained by 50 μg/mL propidium iodide 
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(PI) solution with 100 μg/mL RNase A in dark for 30 minutes. Cells were analyzed using 
a FACSCalibur flow cytometer. 
3.14 Drug Treatment 
          mRNA stability assay was accomplished by inhibition of global RNA synthesis 
through the use of pharmacological inhibitor Actinomycin D (ActD). Cells were treated 
with ActD at 5 ng/mL for 0, 3, 6 and 9 hours. At the end of incubation time point, medium 
was removed and cells were directly lysed on dish with Trizol reagent. 
3.15 Trypan Blue Exclusion Assay 
          This assay was performed to determine cell death. Briefly, cells were left untreated 
or treated with TGF-β1 at 10 ng/mL for indicated periods of time. At the end of incubation 
time point, all cells (both adherent and floating) were harvested, stained with trypan blue 
and counted immediately to determine the percentage of nonviable cells (stained blue). 
Columns represent the mean of three independent measurements and bars represent 
standard error.  
3.16 RNA-sequencing (RNA-seq) 
          Total RNAs isolated from T47D, T47D-RBMS3, T47D-ESRP1 KO, T47D-ESRP2 
KO, T47D-ESRP DKO and T47D-ESRP DKO-RBMS3 cells using RNeasy Mini Kit 
(Qiagen). RNA integrity and concentration were determined using Bioanalyzer (BioTek) 
and agarose gel electrophoresis. The purified samples were sequenced and the clean reads 
were mapped against human genome. The normalized expression values for each gene 
were quantified using log2FPKM value (expected number of fragments per kilo base of 
transcript sequence per million base pairs sequenced). The transcript levels of genes having 
a fold change (FC) of greater than 0.5 were significantly differential between two samples. 
The software Morpheus(https://software.broadinstitute.org/morpheus/) was used to draw 
heatmap. 
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3.17 Functional Enrichment Analysis for DEGs 
          DEG sets were screened out for functional enrichment analysis. Essentially, Gene 
Ontology (GO) terms for biological processes, cellular components and molecular function 
categories were annotated by two public resources: GO (http://geneontology.org/) and 
Metascape (http://metascape.org/) [142-144]. Only terms with p-value <0.01 and the 
number of enriched genes greater than 3 were considered as significant. All resultant terms 
were then grouped into clusters based on their similarities. The most enriched term within 
a cluster was chosen to represent the cluster. DEG sets were also used to conduct gene set 
enrichment analysis (GSEA), which was performed with GSEA v3.0 on various functional 
characteristic gene signatures.  Gene sets were obtained from Molecular Signature 
Database (MSigDb).  
3.18 Breast Cancer Survival Analysis 
          Kaplan-Meier survival analyses for clinical outcomes (RFS or DMFS) of breast 
cancers were performed using web tool Kaplan-Meier Plotter (http://kmplot.com/analysis/) 
and UCSC Xena tool (https://xenabrowser.net/). The percentiles of the patients between 
the upper and lower quartile were auto-selected based on the best performing thresholds as 
cutoffs. 
3.19 Correlation analysis 
          Correlation analysis was analyzed with the Gene Expression Profiling Interactive 
Analysis (GEPIA) online analysis tool, which uses the BRCA dataset from TCGA database 
(http://gepia2.cancer-pku.cn/). 
3.20 Human Breast Cancer Tissue Dataset Analysis 
          mRNA expression analysis of breast tumor datasets was conducted on web tool 
Oncomine (https://www.oncomine.org/). Correlation analysis was analyzed with the Gene 
Expression Profiling Interactive Analysis (GEPIA) online analysis tool, which uses the 
BRCA dataset from TCGA database. (http://gepia2.cancer-pku.cn/). 
42 
 
3.21 Statistical analysis 
          Experiments were repeated at least twice. Data are presented as mean ± SD. A 
Student’s t-test (two tailed) was used to compare two groups. p < 0.05 was considered 
statistically significant. 
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CHAPTER 4. RESULTS 
4.1 RBMS3 is correlated with malignance of breast cancer 
To determine whether rbms3 mRNA expression is altered in breast cancer, we 
interrogated gene expression datasets of human breast cancer samples from Oncomine 
database. According to Turashvili and colleagues’ dataset, high level of rbms3 was found 
in the invasive lobular breast carcinoma compared to ductal and lobular breast cells (Figure 
4.1A). In Curtis dataset, 5 phyllodes tumor samples and 144 paired normal breast samples 
were analyzed (Figure 4.1B). The mRNA expression of rbms3 was significantly increased 
in phyllodes tumor samples when compared with normal controls. Interestingly, additional 
analysis on Finak dataset of 53 breast tumor stroma samples and 6 normal breast stroma 
samples revealed that the mRNA level of rbms3 was found significantly higher in the 
invasive breast carcinoma stroma compared with normal breast stroma (Figure 4.1C). In 
addition, rbms3 transcript was found to be to be absent in noninvasive luminal breast 
cancer cell lines MCF7, T47D and SK-BR-3 (Figure 4.2). Our microarray dataset indicated 
significant upregulation of rbms3 in the triple-negative breast cancer (TNBC) cells 
compared with luminal BC MCF7 cells (Figure 4.3A). Based on gene expression profiles 
from Cancer Cell Line Encyclopedia (CCLE) dataset, rbms3 was also markedly increased 
in the BLBC cell lines (MDA-MB-157, MDA-MB-231, Hs578T and BT549) compared to 
luminal breast cancer cell lines (MCF7, T47D and ZR-751) (Figure 4.3B). IHC staining 
from the Human Protein Atlas database showed higher protein expression of RBMS3 in 
myoepithelial cells as compared to ajacent luminal cells (Figure 4.4). Using UCSC Xena 
online tool, we found that high expression of rbms3 predicts lower overall survival in 1273 
samples from TCGA BRCA dataset (Figure 4.5A). Furthermore, Kaplan-Meier Plotter 
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(KM Plotter) revealed that higher expression of rbms3 correlated with lower distant 
metastasis free survival (DMFS) using microarray data from 1746 breast cancer samples 
(Figure 4.5B).  KM Plotter also predicted lower DMFS for low expression of rbms3 in 458 
samples of grade 3 breast cancer patients (Figure 4.5C). Altogether, these data suggest that 
RBMS3 correlates with breast cancer malignancy. 
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Figure 4.1 Rbms3 is upregulated in invasive breast carcinoma  
(A) Comparison of rbms3 mRNA expression between invasive breast tissue and normal 
breast cells in Turashvili dataset (P<0.05). (B) Comparison of rbms3 mRNA expression 
between normal breast cells and breast phyllodes tumor in Curtis dataset (P<0.001). (C) 
Comparison of rbms3 mRNA expression between the stroma of invasive breast carcinoma 
versus that of normal breast tissue in Finak dataset (P<0.05). Two-sample t-test was used 
to compare rbms3 gene expression between carcinoma and normal samples. The 
expression values were log2-transformed median-centered ratio. (data from Oncomine 
database) 
 
46 
 
                    
Figure 4.2 Rbms3 is undetected in luminal and HER2+ subtype BC cell lines  
Rbms3 mRNA in luminal MCF7 and T47D breast cancer cells, HER2-overexpressing SK-
BR-3 breast cancer cells, hTERT-HME1 normal breast cells and four fibroblast cell lines 
(BJ, BJ hTERT+, fHDF/TERT166 and HBF TERT88) in the Human Protein Atlas database. 
Expression quantification was shown as TPM (Transcripts Per Million). ND indicates no 
transcripts detected. 
 
  
Figure 4.3 Rbms3 is significantly increased in metastatic TNBC cell lines 
(A) Analysis from microarray expression dataset contained 1 luminal (MCF7) and 4 triple-
negative/basal-like (MDA-MB-157, MDA-MB-231, HS578T and BT549) breast cancer 
cell lines.  
(B) Analysis from CCLE expression dataset contained 3 luminal (MCF7, T47D and ZR-
751) and 4 triple-negative/basal-like (MDA-MB-157, MDA-MB-231, HS578T and BT549) 
breast cancer cell lines. 
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Figure 4.4 RBMS3 is found in the basal-like myoepithelial cells but not in adjacent 
luminal cells 
Representative IHC stain of RBMS3 in normal breast tissue from the Human Protein Atlas 
database. Brown color stains for RBMS3 protein. Scale bar, 250 μm. 
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Figure 4.5 Rbms3 is correlated with poor survival in BC patients 
(A) Kaplan Meier plot of overall survival based on rbms3 gene expression in 1247 samples 
from TCGA breast cancer (BRCA) dataset using UCSC Xena tool. Results were shown in 
quartiles. p value < 0.05  
(B)Kaplan Meier plot of distant metastasis-free survival based on rbms3 gene expression 
in 1746 breast cancer patients. p value <0.05 [145] 
(C) Kaplan Meier plot of distant metastasis-free survival based on rbms3 gene expression 
in 458 breast cancer patients (grade 3). p value < 0.001 [145] 
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4.2 RBMS3 induces cell migration, invasion, EMT and CSC traits 
EMT program can impart several traits that are essential to the malignant 
progression of carcinoma cells, including tumor-initiating properties, motility, the ability 
to disseminate and increased tolerance to conventional chemotherapeutics [29, 146-148]. 
To investigate the functional effects of RBMS3, ectopic expression of RBMS3 was induced 
in two luminal breast tumor cell lines, T47D and MCF7, which contain little or no 
endogenous RBMS3. To study whether RBMS3 affects breast cancer cell viability, we 
performed cell viability assay in MCF7 and T47D cells stably expressed control or RBMS3 
vector. MCF7-RBMS3 and T47D-RBMS3 cells demonstrated minimal effect on cell 
growth compared to control cells over the 96-hour interval examined (Figure 4.6A and B). 
Next, we tested migration and invasiveness of these cells using Boyden chamber. RBMS3 
expression markedly increased MCF7 cell migration and invasive capacity (Figure 4.7). 
Similar results were also observed in T47D and MCF10A cells (data not shown). RBMS3 
induced morphologic changes reminiscent of EMT, including downregulation of epithelial 
marker CDH1 and upregulation of mesenchymal markers (TWIST1, TWIST2, SNAI1, 
SNAI2, FOXC1 and FN1) in T47D cells. In addition, T47D-RBMS3 cells lost luminal 
markers CD24 and gained expression of stem cell molecule Sox2 (Figure 4.8A). Similar 
qPCR results were also seen in MCF7-RBMS3 cells (Figure 4.8B). Consistently, RBMS3 
expression decreased the protein levels of epithelial marker E-cadherin, and induced the 
protein levels of stem cell molecules (Sox2 and LSD1) in MCF7 and T47D cells (Figure 
4.9). These data suggest RBMS3 is critical in controlling the expression of EMT and 
pluripotency genes.  
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Figure 4.6 RBMS3 has minimal effect on MCF7 or T47D cell growth 
Graphic representation of cell growth rates by MCF7 (A) and T47D (B) cells stably 
expressed RBMS3 or control vector. Cell viability was measured daily over a 4-day period. 
Presented data are the mean ± SD from three independent experiments. 
 
 
Figure 4.7 RBMB3 promotes MCF7 cell migration and invasion 
Graphic representation of the invasiveness of T47D cells stably expressed control or 
RBMS3 vector using a modified Boyden Chamber migration (A) or invasion (B) assay. 
Quantification is shown in the right panel. Presented data are the mean ± SD from two 
independent experiments in triplicates, with *** indicates p value < 0.001 when comparing 
with control values. Scale bars, 100 μm. 
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Figure 4.8 RBMS3 induces the mRNA levels of EMT and stem cell markers 
(A-B) Real-time PCR analysis of the mRNA level of several EMT markers and stem cell 
markers in T47D cells or MCF7 cells expressed control or RBMS3 vector. Data are shown 
as mean ± SD from three independent experiments in triplicates. 
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Figure 4.9 RBMS3 induces protein expression of EMT and stem cell markers 
Western blot analysis of EMT marker (E-cadherin) and stem cell markers (Sox2 and LSD1) 
in T47D and MCF7 cells stably expressed control or RBMS3 vector. GAPDH was loaded 
for normalization. 
4.3 RBMS3 promotes cancer stem cell (CSC)-like characteristics 
Cancer cells that develop the ability to undergo EMT lose anchorage dependence 
and thus can detach from the primary tumor. Soft-agar assay was performed in T47D cells 
to determine whether RBMS3 affects anchorage-dependent growth of these cells. RBMS3 
expression resulted in ~ two-fold increase and ~ five-fold increase in the number of soft-
agar colonies in T47D and MCF7 cells, respectively (Figure 4.10). Tumorsphere formation 
is largely dependent upon the self-renewal and tumorigenic abilities of stem/progenitor 
cells, known as cancer stem cells (CSCs), to survive and growth in serum-free suspension. 
Cells are grown in serum-free, non-adherent conditions in order to CSC/progenitor cells 
since only CSC/progenitor cells can survive and proliferate under such environment . CSCs 
is known as the main reason for cancer recurrence, metastasis and therpeutic resistance 
[149]. To study the role of RBMS3 in tumorsphere formation, we cultured MCF7 cells 
expressed control or RBMS3 vector in serum-free suspension medium for two weeks and 
then examined tumorsphere formation of these cells by looking at their size and density. 
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MCF7 control cells formed moderate numbers of mammospheres with similar average 
sizes (30-100 μm). Surprisingly, MCF7-RBMS3 cells appeared to form mammospheres of 
varying sizes. Quantification of tumorsphere counts suggested that while RBMS3 
expression led to moderate decrease in mammospheres of sizes above 30µm, it also led to 
dramatic increase in small irregular cell aggregates/clusters below 30 μm (not strictly 
consider as tumorsphere) or even mini cell clusters (Figure 4.11). Formation of varying 
sizes of mammospheres, especially those mini clusters, is particularly favorable for tumor 
cell dissemination in the circulation. Similar results were also observed in T47D-RBMS3 
cells (data not shown). These results, together with qPCR and western blot results, indicate 
that RBMS3 may enhance CSC-like properties in luminal breast cancer cells.  
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Figure 4.10 RBMS3 promotes colony formation in MCF7 and T47D cells 
Data of colony formation assay are presented as a percentage of vector control cell lines. 
Data are shown as mean ± SD in two independent experiments in triplicates. (***p < 0.001) 
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Figure 4.11 RBMS3 promotes tumorsphere formation in BC cells  
(A) Tumorsphere formation was assessed in MCF7 cells stably expressed control or 
RBMS3 vector. Representative images of tumorspheres are shown. Scale bars, 1000 μm. 
(B) Data of tumorsphere formation assay are presented as counts (size over 30 μm) or 
folds of control vector values (size between 10-30 μm), with mean ± SD of two 
independent experiments performed in triplicates (***p < 0.001). 
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4.4 Loss of RBMS3 Suppresses EMT and CSC population 
To further explore the function of RBMS3 in TNBC cells, we established stable 
RBMS3-knockout clones in BT-549, Hs578T, MDA-MB-157 and MDA-MB-231 cells by 
CRISPR/Cas9 technique. BT-549 cells appeared with stellate projections, whereas BT549-
RBMS3 KO cells exhibited a marked change in morphology, with rounded/polygonal 
shape when cultured at low density (Figure 4.12). To investigate whether RBMS3 affects 
breast cancer cell growth, we measured cell growth rates in BT-549 cells by cell viability 
assay. Over the time course examined, RBMS3 knockout demonstrated significant 
decrease on cell growth in BT-549 cells (Figure 4.13). We also measured cell growth in 
Hs578T cells by cell counting. Knockout of RBMS3 resulted in significant decrease in 
growth rate in Hs578T cells (Figure 4.14). To investigate the migratory ability mediated 
by RBMS3 in TNBC cells, transwell assay was performed BT-549 and MDA-MB-157 
cells. Indeed, loss of RBMS3 significantly inhibited cell migration (Figure 4.15). This 
finding was supported by in vitro wound healing assay in MDA-MB-231 cells. Closure of 
the scratch wound required significantly longer time in RBMS3-depleted cells than in 
control cells. Statistical analysis indicated that migratory activity of RBMS3-depleted cells 
was 60% lower than that of control cells (Figure 4.16). Loss of RBMS3 led to significant 
upregulation of epithelial markers (CDH1 and FOXA1) and downregulation of several 
mesenchymal markers (SNAI2, TWIST1, TWIST2, CDH2, FN1 and FOXC1) in BT549 cells 
(Figure 4.17). Importantly, RBMS3 depletion reduced the protein levels of epithelial 
marker E-cadherin, while increased the protein levels of mesenchymal markers (Slug, 
Twist, Vimentin, Snail and N-cadherin) in BT549 and MDA-MB-157 cells, as confirmed 
by western blotting (Figure 4.18). To test whether RBMS3 affected CSC characteristics, 
BT549 control and RBMS3 knockout cells were subjected to FACS analysis using 
CD44high/CD24low and CD49fhigh/CD24low/EpCAM+ as surface markers. The 
CD44high/CD24low and CD49fhigh/CD24low/EpCAM+ CSC populations (represented by the 
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upper left quadrant) were both dramatically decreased in RBMS3-depleted cells vs. control 
cells, confirming that RBMS3 positively regulates CSC traits (Figure 4.19). Altogether, 
the above findings further support the role of RBMS3 as a crucial factor in promoting breast 
cancer cell migration, invasion, EMT as well as CSC characteristics. 
 
 
Figure 4.12 Loss of RBMS3 reduces mesenchymal phenotype in BT549 cells 
Representative images of BT549 cells with or without loss of RBMS3. At low cell density, 
BT549 cells exhibit elongated spindle-like shape, whereas RBMS3 KO cells show 
shortened, polygonal and spread-out shape. Scale bars, 400 μm. 
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Figure 4.13 Loss of RBMS3 significantly inhibits BT549 cell viability 
Graphic representation of cell viability in BT549 cells with or without loss of RBMS3 
over a 3-day period measured by CellTiter-Glo 2.0 Assay. Presented data are the mean 
± SD from three independent experiments. (*p < 0.05) 
 
                    
Figure 4.14 Loss of RBMS3 significantly decreases Hs578T cell growth 
Graphic representation of cell growth rates in Hs578T cells with or without loss of 
RBMS3 over a 3-day period measured by cell counting. Presented data are the mean ± 
SD from three independent experiments. (*p < 0.05) 
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Figure 4.15 Loss of RBMS3 inhibits BT-549 and MDA-MB-157 cell migration 
Graphic representation of the invasiveness of MDA-MB-157 and BT-549 cells with or 
without loss of RBMS3 using a modified Boyden Chamber migration assay. Quantification 
is shown in the right panel. Presented data are the mean ± SD from two independent 
experiments in triplicates, with ** indicates p value < 0.01, *p <0.05 when comparing with 
control values. Scale bars, 100 μm. 
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Figure 4.16 Loss of RBMS3 prevents wound closure in MDA-MB-231 cells 
Representative images of scratch assay in MDA-MB-231 cells with or without loss of 
RBMS3. Distance of wound closure was measured at 0 and 24h. Red dashed lines show 
the margins of migrating cells. Scale bars, 1000 μm. (G) Western blot analysis of RBMS3 
knockout in MDA-MB-231 cells and statistical analysis of 10 random measurements of 
scratch assay. (***p < 0.001) (H) Migratory ability of MDA-MB-231 and BT549 cells 
and the corresponding RBMS3 knockout cells were analyzed by transwell migration 
assay. Scale bars, 200 μm. (I) Invasive ability of MDA-MB-231 and BT549 cells and 
the corresponding RBMS3 knockout cells were analyzed by transwell invasion assay.  
Scale bars, 200 μm. 
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Figure 4.17 Loss of RBMS3 reduces mesenchymal markers and increases epithelial 
markers at mRNA level 
Real-time PCR analysis of the mRNA level of several mesenchymal markers (SNAI1, 
SNAI2, TWIST1, TWIST2, CDH2, FN1, FOXC1) and epithelial markers (CDH1, FOXA1) 
in BT549 cells with or without loss of RBMS3. Data are shown as mean ± SD from two 
independent experiments in triplicates. (*p < 0.05, **p < 0.01, *** < 0.001, NS = not 
significant) 
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Figure 4.18 Loss of RBMS3 reduces mesenchymal markers and increases epithelial 
markers at protein level 
Western blot analysis of EMT markers in BT549 and MDA-MB-157 cells with or without 
loss of RBMS3. β-actin was loaded as control. 
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Figure 4.19 Loss of RBMS3 reduces CD44high/CD24low and 
CD49fhigh/CD24low/EpCAM+ CSC populations 
Representative FACS images from BT549 cells with or without loss of RBMS3 using 
CD44high/CD24low or CD49fhigh/CD24low/EpCAM+ as surface markers. Quantification of 
CSC populations are shown in the right panel; Presented data are the mean ± SD from three 
experiments. (***p < 0.001) 
4.5 RBMS3 is correlated with TGF-β Signaling 
To further investigate the molecular mechanism of RBMS3 involved in the 
metastasis of breast cancer, T47D cells expressed control or RBMS3 vector were selected 
for RNA-seq analysis to screen for potential targets of metastasis. GO biological analysis 
of deregulated genes (DEGs) between RBMS3 vs. control list revealed top 20 significant 
pathways, including genes encoding ECM-associated proteins, GPCR ligand binding and 
chemotaxis-associated proteins, etc. (Figure 4.20). A subset of enriched terms was selected 
for network plot (Figure 4.21) and protein-protein interaction networks were shown using 
Metascape platform (Figure 4.22-23 and Table 2). Table 3 shows a list of top 20 DEGs 
discovered in the RNA-seq dataset. Gene set enrichment analysis (GSEA) indicated an 
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enrichment of pathway of EMT, inflammatory response, hypoxia and TGF-β signaling in 
T47D-RBMS3 cells compared with T47D control cells (Figure 4.24). In addition, positive 
correlation between RBMS3 and apical junction pathway as well as other pathways was 
also found in T47D-RBMS3 cells (Table 4).  Significant correlation of RBMS3 with EMT 
and TGF-β signatures was also observed in the BRCA dataset from TCGA database using 
GEPIA2 online analysis tool (Figure 4.25). A8301 prevents phosphorylation of Smad2/3, 
leading to decreased Smad-dependent TGF-β signaling. TGF-β1 treatment inhibited the 
expression of its downstream target CTGF in T47D cells, which was potentiated by Alk5 
inhibitor A8301, suggesting that TGF-β1-mediated downregulation of CTGF is mediated 
mainly through non-Smad pathways. Overexpression of RBMS3 in T47D cells led to 
significantly downregulated CTGF expression, which was enhanced by TGF-β1 treatment. 
A8301 treatment, however, failed to reverse downregulation of CTGF, indicating that 
RBMS3-mediated CTGF downregulation was mainly regulated through non-Smad 
pathways (Figure 4.26). We also noticed that overexpression RBMS3 facilitated TGF-β1-
mediated downregulation of E-cadherin in MCF7 cells (Figure 4.27). 
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Figure 4.20 Functional enrichment analysis of deregulated gene set (DEGs)  
The DEG list of T47D-RBMS3 cells (vs. T47D control) was subjected to enrichment 
analysis using Gene Ontology (GO) terms for biological processes, cellular components 
and molecular function categories annotated by Gene Ontology. Data represented as fold 
enrichment. 
 
 
Figure 4.21 Heatmap for GO analysis of DEGs showing top 20 significant pathways 
The DEG list of T47D-RBMS3 cells (vs. T47D control) was subjected to pathway and 
process enrichment analysis with ontology sources: Kyoto Encyclopedia of Genes and 
Genomes (KEGG) Pathway, GO Biological Processes Reactome Gene Sets, Canonical 
Pathways and CORUM. All genes in the genome were included as the enrichment 
background. P-value was calculated based on accumulative hypergeometric distribution. 
Enrichment factor is the ratio between the observed counts and the counts expected by 
chance. Terms with a p-value < 0.01, a minimum count of 3, and enrichment factor > 1.5 
are collected and grouped into clusters based on their similarities. The most statistically 
significant term within a cluster is chosen to represent the cluster. p<0.05 
(http://metascape.org/) 
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Figure 4.22 Network of Enriched Terms 
To further capture the relationships between the terms, a subset of enriched terms was 
selected as a network plot, where terms with a similarity > 0.3 was connected by edges. 
The terms with the best p-value from each of the 20 clusters, with constraints that no more 
than 15 terms per cluster and no more than 250 terms in total, were selected to be visualized. 
Each node represents an enriched term and is colored by its cluster ID or p-value. a) colored 
by cluster ID, where nodes that share the same cluster ID are typically close to each other; 
b) colored by p-value, where terms containing more genes tend to have a more significant 
p-value. Results displayed in ‘cose’ layout format. (http://metascape.org/) 
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Figure 4.23 Protein-protein Interaction Network and MCODE Components 
Protein-protein interaction enrichment analysis was carried out in the DEG list of T47D-
RBMS3 cells vs. control cells via the Metascape platform, which utilizes the following 
databases: BioGrid, InWeb_IM and OmniPath. This network plot contains the subset of 
proteins that form physical interactions with at least one other member in the list. The 
Molecular Complex Detection (MCODE) algorithm has been applied to identify and 
assemble network components for individual gene lists. Pathway and process enrichment 
analysis was applied to each MCODE component independently, and 2-3 best-scoring 
terms by p-value are retained as functional description of the corresponding components, 
shown in Table 3.  
 
Table 2 Protein-protein interaction network and MCODE components identified in 
the DEG list of T47D-RBMS3 vs. T47D cells 
Color MCODE GO Description Log10(P) 
 
MCODE_1 R-HSA-418594 G alpha (i) signaling events -39.3 
 
MCODE_1 R-HSA-373076 Class A/1 (Rhodopsin-like 
receptors) 
-32.6 
 
MCODE_1 R-HSA-500792 GPCR ligand binding -32.3 
 
MCODE_2 R-HSA-
2262752 
Cellular responses to stress -13.3 
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MCODE_2 R-HSA-
8953897 
Cellular responses to external 
stimuli 
-12.4 
 
MCODE_2 hsa05322 Systemic lupus erythematosus -11.6 
 
MCODE_3 R-HSA-416476 G alpha (q) signaling events -28.8 
 
MCODE_3 R-HSA-373076 Class A/1 (Rhodopsin-like 
receptors) 
-26.3 
 
MCODE_3 R-HSA-500792 GPCR ligand binding -24.2 
 
MCODE_4 R-HSA-418555 G alpha (s) signaling events -13.2 
 
MCODE_4 R-HSA-500792 GPCR ligand binding -11.2 
 
MCODE_4 GO:0008277 regulation of G protein-coupled 
receptor signaling pathway 
-9.3 
 
MCODE_6 GO:0006790 sulfur compound metabolic 
process 
-8.3 
 
MCODE_6 GO:0005975 carbohydrate metabolic process -7.2 
 
MCODE_6 GO:1901137 carbohydrate derivative 
biosynthetic process 
-6.7 
 
MCODE_7 hsa05217 Basal cell carcinoma -9.9 
 
MCODE_7 R-HSA-195721 Signaling by WNT -9.3 
 
MCODE_7 GO:0060070 canonical Wnt signaling 
pathway 
-9.3 
 
MCODE_8 R-HSA-211897 Cytochrome P450 - arranged by 
substrate type 
-12.9 
 
MCODE_8 R-HSA-211945 Phase I - Functionalization of 
compounds 
-11.8 
 
MCODE_8 R-HSA-211859 Biological oxidations -10.2 
 
MCODE_9 R-HSA-
3928665 
EPH-ephrin mediated repulsion 
of cells 
-10.8 
 
MCODE_9 GO:0048013 ephrin receptor signaling 
pathway 
-9.8 
 
MCODE_9 R-HSA-
2682334 
EPH-Ephrin signaling -9.7 
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MCODE_12 R-HSA-983168 Antigen processing: 
Ubiquitination & Proteasome 
degradation 
-5.7 
 
MCODE_12 GO:0000209 protein polyubiquitination -5.7 
 
MCODE_12 R-HSA-983169 Class I MHC mediated antigen 
processing & presentation 
-5.4 
 
MCODE_13 R-HSA-
8856825 
Cargo recognition for clathrin-
mediated endocytosis 
-7.1 
 
MCODE_13 R-HSA-
8856828 
Clathrin-mediated endocytosis -6.7 
 
MCODE_13 R-HSA-199991 Membrane Trafficking -4.7 
 
MCODE_17 GO:0016584 nucleosome positioning -9.5 
 
MCODE_17 GO:0031936 negative regulation of chromatin 
silencing 
-9.3 
 
MCODE_17 GO:0031935 regulation of chromatin 
silencing 
-8.4 
 
MCODE_18 M3008 NABA ECM 
GLYCOPROTEINS 
-6.3 
 
MCODE_18 M5884 NABA CORE MATRISOME -5.8 
 
MCODE_19 GO:0046580 negative regulation of Ras 
protein signal transduction 
-8.1 
 
MCODE_19 GO:0051058 negative regulation of small 
GTPase mediated signal 
transduction 
-7.9 
 
MCODE_19 R-HSA-
6802949 
Signaling by RAS mutants -7.8 
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Table 3 List of the top 20 DEGs in T47D-RBMS3 vs. T47D cells from RNA-seq 
expression dataset. 
Genes Upregulated (FC) Genes Downregulated (FC) 
RP11-9J18.1 3.626461 KRT16 -4.216279341 
ANGPT1 3.269688 GREM2 -3.176657388 
CLDN16 3.126702 HIST1H4D -2.662753541 
CRABP1 2.870269 CLEC3A -2.479534141 
GALNT5 2.759951 HPSE2 -2.350982455 
CLDN1 2.484171 LA16c-312E8.5 -2.326493157 
HBA1 2.387961 HIST1H1B -2.135837845 
LDHB 2.342741 TNFRSF11A -2.0021068 
FAM25A 2.103505 OR52E6 -1.908076923 
EPHA6 2.062273 LMO4 -1.875299924 
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Figure 4.24 GSEA showing an enrichment of several pathways 
Gene Set Enrichment Analysis (GSEA) showing an enrichment of the following pathways 
using DEG list of T47D-RBMS3 versus T47D control cells: EMT, inflammatory response, 
apical junction, hypoxia and TGFβ-related gene signatures. NES indicates normalized 
enrichment score.  
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Table 4 Selected pathways from GSEA analysis with highest ranked NES (>1.00) 
indicating high probability of positive correlation. 
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Figure 4.25 Correlation of RBMS3 and EMT/ TGFβ-related gene signatures 
Correlation analysis was performed on the Gene Expression Profiling Interactive Analysis 
version 2 (GEPIA2) online analysis tool, which analyzes BRCA dataset from TCGA 
database. R denotes correlation efficient. TPM, transcript per million.  a) Correlation 
between RBMS3 and seven EMT signatures (SNAI1, SNAI2, TWIST1, TWIST2, ZEB1, 
ZEB2, VIM). b) Correlation between RBMS3 and five TGFβ pathway component 
signatures (TGFBR1, TGFBR2, SMAD2, SMAD3 and SMAD4). c) Correlation between 
RBMS3 and four TGFβ pathway targets (PTGS2, CTGF, SMAD7 and SNAI2).  
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Figure 4.26 RBMS3 promotes downregulation of TGF-β1-regulated CTGF gene 
expression in T47D cells 
Real-time PCR analysis of TGF-β downstream gene CTGF level in T47D cells stably 
expressed RBMS3 or control vector treated with TGF-β1 (10 ng/mL) or TGFβR1 inhibitor 
A8301 (5 μM). Data are shown as mean ± SD from two independent experiments in 
triplicates. 
 
 
Figure 4.27  RBMS3 facilitates TGF-β1-mediated downregulation of E-cadherin 
Representative immunofluorescence images of MCF7 cells stably expressing RBMS3 or 
control vector left untreated or treated with TGF-β1 (10 ng/mL) for 24 hours, and then 
immunostained with anti-E-cadherin antibody and DAPI. Scale bars, 40 μm. 
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4.6 RBMS3 alleviates TGF-β1-mediated cytostasis and apoptosis in luminal breast 
cancer cells 
TGF-β signaling features a growth inhibitory effect at premalignant stages of breast 
cancer cells, but aggressive oncogenic activities at advanced malignant state [54, 150]. 
Long term treatment (~two weeks) of TGF-β1 induced massive cell death in MCF7 cells, 
but exerted significantly lower impact on MCF7-RBMS3 cells (Figure 4.28). Since 
RBMS3 posed little impact on MCF7 cell proliferation (Figure 4.6A), this data indicated 
the possibility of RBMS3 in suppressing TGF-β1-induced cell death. To confirm this data, 
MCF7 control and RBMS3-expressing cells were subjected to trypan blue exclusion assay. 
MCF7-RBMS3 cells showed significantly reduced dead cells compared to control cells 
starting at day 3 post treatment of TGF-β1 (Figure 4.29). To determine whether apoptosis 
is the cause of cell death induced by TGF-β1, cells were examined for biochemical and 
morphological markers of apoptosis using Propidium Iodide/Annexin V staining. After 24 
hour TGF-β1 treatment, MCF7-RBMS3 and control cells showed similar baseline 
apoptotic population of 0.6% (data not shown). However, after 72 hours, TGF-β1 induced 
a drastic increase in the apoptotic cell population to 54.3% in control cells versus 36.7% in 
MCF7-RBMS3 cells (Figure 4.30). To study the effect of RBMS3 on the TGF-β1-mediated 
cytostatic effect on MCF7 cells, we examined cell cycle distribution after 24 hour TGF-β1 
treatment. TGF-β1 induced an increase in the fraction of S phase cells and decrease in the 
fraction of G2/M phase MCF7 cells. Upon TGF-β1 stimulation, compared to MCF7 control 
cells, MCF7-RBMS3 showed significantly higher fraction of S phase cells and lower 
fraction of G0/G1 phase cells, suggesting that more cells entered into S phase and that 
RBMS3 seems to prevent the TGF-β1-mediated G1-S phase arrest (Figure 4.31). Upon 24 
hours of TGF-β1 stimulation, MCF7 control cells showed upregulation of pro-apoptotic 
proteins Bad and cleaved Caspase 3, and downregulation of cell cycle protein CDC2 
compared to untreated cells, suggesting increased apoptosis and decreased proliferation in 
the TGF-β1-treated MCF7 cells. Upon TGF-β1 stimulation, however, MCF7-RBMS3 cells 
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showed a reduction in pro-apoptotic protein Bax and unchanged levels of Bad, cleaved 
Caspase 3 and CDC2 compared to untreated cells, suggesting decreased apoptosis and 
unaffected proliferation in these cells (Figure 4.32). These data suggest that RBMS3 may 
alleviate TGF-β1-mediated apoptotic and cytostatic effects on MCF7 cells.  
 
                   
Figure 4.28 RBMS3 suppresses TGF-β1-induced apoptosis in MCF7 cells 
Representative images of MCF7 cells stably expressed control or RBMS3 vector followed 
by administration of EGF (10 ng/mL) and TGF-β1 (10 ng/mL) for two weeks. Relative 
viability is measured by cell counting and data are plotted using untreated MCF7 cells as 
control. Scale bars, 400 μm. Data are shown as mean ± SD from three independent 
experiments. *** p < 0.001 when TGF-β1-treated MCF7-RBMS3 group is compared with 
TGF-β1-treated MCF7 group. 
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Figure 4.29 RBMS3 prevents TGF-β1-induced cell death in MCF7 cells 
Cells were treated with TGF-β (10 ng/mL) for indicated period of time, typsinized and 
counted for nonviable cells with trypan blue. Data were represented as mean ± SD from 
three independent experiments. (NS indicates nonsignificant, * indicates p <0.05) 
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Figure 4.30 Annexin V/PI staining of MCF7-RBMS3 cells treated with TGF-β1 
(A) Representative FACS images from MCF-7 cells expressed control or RBMS3 vector 
with TGF-β1 treatment for 72 hours using Annexin V-FITC Early Apoptosis Detection Kit. 
Annexin V-FITC conjugated protein binds to cell surfaces expressing phosphatidylserine, 
an early apoptosis marker. Cells stained with propidium iodide (PI), a non-cell-permeable 
DNA dye, indicate necrotic cells. Cells stained with both Annexin V-FITC and PI 
demonstrate late stage apoptosis and early necrosis. 
(B) Quantification of apoptotic population between MCF-7 cells expressed control or 
RBMS3 vector under TGF-β1 treatment is shown. Data are shown as mean ± SD from two 
independent experiments. ***p value < 0.005 
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Figure 4.31 RBMS3  facilitates TGF-β1-mediated increase of S-phase population 
Statistical analysis of Cell cycle distribution (G0/G1 phase, S phase or G2/M phase) of 
MCF7 cells stably expressed RBMS3 or control vector. Cells were starved overnight and 
then left untreated or treated with TGF-β1 for 24 hours.  
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Figure 4.32 RBMS3 regulates TGF-β1-mediated apoptosis and cell cycle markers 
Western blot analysis of apoptosis regulators (Bax, Bad, cleaved Caspase 3 and Bcl2) and 
cell cycle regulators (CDC2, CDK2, p21 and p27) in MCF7 cells stably expressed control 
or RBMS3 vector in the presence or absence of TGF-β1 (10 ng/mL) for 24 hours. α-tubulin 
was loaded as control. 
4.7 Loss of RBMS3 Disrupts Smad-dependent TGF-β Signaling 
On the other front, RBMS3 depletion significantly downregulated TGF-β effectors 
Smad2 and Smad3 (Figure 4.33). Furthermore, loss of RBMS3 suppressed TGF-β-
regulated genes (Figure 4.34). Of note, CTGF and PTGS2 are recognized to be drivers of 
breast cancer bone metastasis [151]. RBMS3 depletion led to significant decreases in the 
total level of Smad2, Smad3 and Smad4 protein and the phosphorylation level of Smad2 
and Smad3 in BT549 cells. We also noticed that EMT transcription factors Snail, Slug and 
Twist are significantly reduced upon loss of RBMS3 (Figure 4.35). These data further 
confirm that RBMS3 is involved in TGF-β-mediated EMT. 
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Figure 4.33 Loss of RBMS3 downregulates Smad2 and Smad3 
Real-time PCR analysis of the mRNA expression of TGF-β signaling mediators Smad2, 
Smad3 and Smad4 in BT549 cells with or without loss of RBMS3. ***p <0.001 and NS 
stands for statistically non-significant. Data are shown as mean ± SD from three 
independent experiments in triplicates. 
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Figure 4.34 Loss of RBMS3 downregulates TGFβ1-regulated genes 
Real-time PCR analysis of TGF-β downstream gene PAI1, CTGF, ID2, PTGS2 and Smad7 
levels in BT549 cells with or without loss of RBMS3 treated with TGF-β1 for 0, 2, 4, 8 
hours. Data are shown as mean ± SD from three independent experiments in triplicates. 
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Figure 4.35 Loss of RBMS3 reduces TGF-β1 effector Smad proteins and EMT 
transcription factors 
Western blot analysis of TGF-β signaling mediators (Smad2, p-Smad2, Smad3, p-Smad3 
and Smad4) and mesenchymal markers (Slug, Twist, Snail) in BT549 cells with or 
without loss of RBMS3 left untreated or treated with TGF-β1 at 10 ng/mL. GAPDH was 
loaded for normalization. 
 
4.8  RBMS3 regulates TGF-β signaling by stabilizing Smad transcripts 
Once activated by TGF-β ligands, TGF-β signaling is mediated through Smad and 
non-Smad pathways to regulate transcription, translation, post-translational modifications, 
protein synthesis and RNA biogenesis [56]. In the canonical TGF-β pathway, TGF-β ligand 
binds to the type 2 TGF-β receptor (TGFBR2), which recruits the TGFBR1. The receptors 
dimerize and undergo autophosphorylation, allowing for the recruitment and 
phosphorylation of Smad2/3 by TGFBR1. The activated Smad2/3 dissociate from the 
plasma membrane, hetero-oligomerize with Smad4 and translocate into the nucleus to 
mediate gene expression/repression. Since protein levels changes of Smad2/3 were 
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observed in cells transfected with CRISPR/Cas9-RBMS3 or ectopic RBMS3 in 
comparison with mock-treated controls, we asked whether RBMS3 regulates Smad2/3 
transcripts. To test this possibility, we first examined the subcellular localization of 
RBMS3. As expected, we found that RBMS3 was mainly localized in the cytoplasm, 
suggesting roles in RNA metabolism (Figure 4.36). Next, we asked whether RBMS3 
physically interact with Smad2/3 transcripts. Lentiviral vectors of strep-tagged full-length 
RBMS3 (RBMS3-Strep) and strep-tagged mutant RBMS3 lacking the two putative RNA-
binding domains (dRRM-RBMS3-Strep) were generated, respectively (Figure 4.37A). 
RNA immunoprecipitation assay followed by RT-PCR was performed using cell extracts 
from MDA-MB-231 cells that were induced to express RBMS3-Strep or dRRM-RBMS3-
Strep (Figure 4.37B). We found significant enrichment of Smad2/3 transcripts in MDA-
MB-231 cells expressing RBMS3-Strep compared to dRRM-RBMS3-Strep, indicating 
physical interaction between RBMS3 and Smad2/3 transcripts (Figure 4.38). RNA-binding 
proteins are known to regulate gene expression at post-transcriptional levels, including 
mRNA stability. In zebrafish prechondrogenic crest cells, RBMS3 may regulate the 
stability of Smad2 transcript to control the pool of protein available for signaling [136]. To 
explore whether this mechanism applies to TNBC cells, the mRNA stability of Smad 
transcripts was measured. Upon treatment with transcription inhibitor actinomycin D (5 
μg/ml), knockout of RBMS3 significantly decreased the half-lives of Smad2/3/4 transcripts 
in BT-549 cells (Figure 4.39). Altogether, our results suggest that RBMS3 post-
transcriptionally modulates TGF-β signaling by stabilizing Smad2/3/4 mRNAs. 
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Figure 4.36 RBMS3 is mainly localized in the cytoplasm 
Representative immunofluorescence images of MDA-MB-231 cells stably expressed 
control or Strep-RBMS3 vector immunostained by anti-Strep antibody, visualized by goat 
anti-mouse conjugated with Alexa fluor 568 under confocal microscope. 
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Figure 4.37 Schematic of constructs and RNA-Immunoprecipitation Procedure 
(A)Graphic representation of FL-RBMS3-Strep (full length) and dRRM-RBMS3-Strep 
(RRM motif-deficient) constructs. RRM denotes RNA recognition motif (RRM). Numbers 
of amino acids denote the start and end of each protein segment or motif.  
(B) Graphic representation of general RNA-Immunoprecipitation workflow. Detailed 
protocol is described in Materials and Methods Chapter below. 
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Figure 4.38 RNA-Immunoprecipitation assay showing enrichment of Smad2/3/4 
transcripts 
Real-time PCR analysis of Smad transcripts enriched (fivefold as cutoff, red dashed line) 
for RBMS3-Strep (n=3 experiments). Data are shown as mean ± SD from three 
independent experiments. Other transcripts that are insignificantly enriched are not shown 
here. 
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Figure 4.39 RBMS3 regulates Smad2/3/4 mRNA stability  
Real-time PCR analysis of remaining Smad transcripts (normalized to the level of actin 
transcript) in BT549 cells with or without RBMS3, and plotted along with time after 
Actinomycin D (5 μg/mL) treatment. T1/2 represents relative half-life of the specific Smad 
mRNA in the presence or absence of RBMS3.  
4.9 RBMS3 is negatively correlated with ESRPs expression 
Luminal BC cells are well-known to be rather difficult to become metastatic, 
largely due to presence of intrinsic master regulators that govern the identity of the cell 
type. ESRP1 and ESRP2 (ESRP1/2) are splicing regulators that govern epithelial isoforms 
of proteins during mammalian development. ESRP1/2 are essential for a range of epithelial 
cell properties, such as cytoskeletal dynamics, cell motility, cell-cell junctions and 
pathways involved in EMT [152]. Importantly, loss of ESRP1 and ESRP2 disrupts the 
ability to form a proper epithelial layer, concomitant with increased motility and expression 
of invasive markers, suggestive of acquisition of mesenchymal phenotypes. Therefore, 
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ESRPs are known to suppress EMT in various cancers. Our microarray dataset suggested 
Esrp1 and Esrp2 are overexpressed in luminal BC cells but repressed in BLBC cells, which 
is consistent with western blotting results (Figure 4.40-42). While ESRP1 contains 4 
RRMs, a DnaQ-like 3’-5’ exonuclease domain superfamily (DEDD) and a Domain of 
Unknown Function (DUF), ESRP2 contains 3 RRMs and a DEDD (Figure 4.43). To better 
understand the roles of ESRPs and RBMS3, we generated stable ESRP knockout clones 
and RBMS3 overexpression clones and subjected them to functional assays and RNA-seq. 
Western blotting suggested successful establishment of these clones (Figure 4.44-45). By 
appearance, T47D-ESRP1 KO cells are more stretched and edged, whereas T47D-ESRP2 
KO cells appear more rounded and organized than control cells. T47D-ESRP DKO cells 
attach loosely to dishes, instead, they tend to aggregate to form clusters or grow on stacks. 
Surprisingly, T47D-ESRP DKO-RBMS3 cells regains the ability to attach to dishes, an 
indication that RBMS3 is involved in cell adhesion and spreading. None of the cell lines 
showed a typical mesenchymal appearance of a spindle-like shape, even in the presence of 
TGF-β (Figure 4.46). Despite of this, we asked whether RBMS3 contribute to the EMT 
process by ectopically expressing an EMT transcription factor Slug in each of the T47D-
derived clones. Indeed, at day 9 post transfection, we noticed that Slug overexpression in 
T47D-ESRP DKO-RBMS3 cells resulted in ~ 12-fold increase in spindle-like shaped cells 
than Cas-9 expressing control cells, compared to the 3 ~ 4 fold increase in cells with loss 
of ESRP1/2 or RBMS3 expression (Figure 4.47). This suggests that RBMS3 may 
predispose the cells to a state that is prone to EMT. Moreover, long term expression (over 
10 days) of EMT transcription factors Slug or Snail led to significant apoptosis in T47D 
cells with or without loss of ESRP1 or ESRP2. Overexpression of Twist in T47D cells 
with or without loss of ESRP1 also induced apoptosis, but not in cells with loss of 
ESRP2. Interestingly, loss of both ESRPs almost completely abolished apoptosis 
mediated by Slug, Snail or Twist (data not shown). The effects of TGF-β, Snail, Slug and 
Twist on the apoptosis and appearance of these cells lines are summarized in Table 5. 
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Figure 4.40 Rbms3 is inversely correlated with ESRP1 and ESRP2 in TNBC cells 
compared to luminal BC cells (RNA-seq) 
Data from CCLE RNA-seq expression dataset contained 3 luminal (MCF7, T47D and ZR-
751) and 4 basal-like/triple negative (MDA-MB-157, MDA-MB-231, Hs578T and BT549) 
BC cell lines.  
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Figure 4.41 Rbms3 is inversely correlated with ESRP1 and ESRP2 in TNBC cells 
compared to luminal BC cells (microarray) 
Microarray Data dataset from our group contained luminal MCF7 cells and 3 basal-
like/triple negative (MDA-MB-157, MDA-MB-231, Hs578T and BT549) BC cell lines.  
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Figure 4.42 RBMS3 is inversely correlated with ESRP1 and ESRP2 expression in 
TNBC cells compared to luminal BC cells 
Western blot analysis contained 2 luminal cell lines (MCF7 and T47D) and 7 TNBC cell 
lines (including inflammatory BC cells SUM149 and 6 BLBC cells MDA-MB-157, MDA-
MB-231, Hs578T, BT549, SUM159 and SUM1315).  
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Figure 4.43 Schematic of the domain organization of ESRP1, ESRP2 and RBMS3 
DEDD: DnaQ-like 3’-5’ Exonuclease Domain superfamily; RRM: RNA Recognition 
Motif; DUF: Domain of Unknown Function. RBMS3 contains two RRMs that are known 
to bind single-stranded RNAs. 
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Figure 4.44 Schematic workflow for establishment of  RBMS3 overexpression and 
ESRP knockout cell lines 
All knockout cell lines were established on the Cas9-expressing cells. Each transfected cell 
line was either selected by corresponding drug for at least two weeks or cell sorting. All 
knockout cells were screened for single clones. A total of 14 cell lines were subjected to 
functional assays and RNA-seq.  
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Figure 4.45 Establishment of ESRP-KO and RBMS3-OE cell lines 
Western blot analysis of RBMS3 overexpression and ESRP knockout cell lines. (Ctrl 
denotes control/parental cells; E1KO denotes ESRP1 knockout; E2KO denotes ESRP2 
knockout; DKO denotes ESRP1 and 2 double knockout; DKOR3 denotes ESRP 1 and 2 
double knockout combined with RBMS3 overexpression) 
 
 
 
 
 
 
 
 
96 
 
 
 
 
 
Figure 4.46 The effect of TGF- β1 on MCF7-derived or T47D-derived cells 
Combination of RBMS3 expression and TGF- β1 treatment (10 ng/mL) does not contribute 
to typical mesenchymal appearance in MCF7 or T47D cells with loss of ESRP1 and ESRP2 
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Figure 4.47 RBMS3 facilitates Slug-induced EMT 
MCF7-derived cell lines stably expressed Slug-mCherry vector were plated for 24 hours 
and treated with TGF-β1. Cells were cultured for 9 days and photographs were taken. 
Representative images of the cells and fluorescence intensity of mCherry from the same 
views are shown. Scale bars, 400 µm. Expression level of Slug was confirmed by Western 
blot (data not shown). Red arrows show the area of cells with mesenchymal-like 
morphology. The ratio between the longest diameter and the shortest diameter of the cells 
was determined. Cells for which the ratio was more than 2.1 was regarded as ‘spindle-like 
shaped cells’. Data are shown as mean ± SD from three independent experiments. (*p < 
0.05, **p < 0.01, *** < 0.001) 
*** 
* * ** 
* 
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4.10 RBMS3 and ESRPs play different roles in cell proliferation and migration 
To examine the functions of ESRPs in detail and compare with RBMS3, we first 
performed cell viability assay. Compared to MCF7-Cas9 control cells, loss of ESRP2 
demonstrated significantly elevated cell growth, indicative of potent growth suppressive 
role of ESRP2. Unlike ESRP2, loss of ESRP1 had little effect on MCF7 cell viability. Loss 
of both ESRPs showed a slight increase of cell growth compared to control, whereas 
overexpression of RBMS3 induced a significantly increased cell growth in MCF7-ESRP 
DKO cells. RBMS3 induced little/no increase on cell growth compared with MCF7 or 
T47D control cells. Loss of ESRP1 caused mild reduction of cell viability compared to 
T47D-Cas9 control cells, suggesting that ESRP1 has mild growth-promoting function in 
T47D cells. Conversely, loss of ESRP2 resulted in significant increase in T47D cell 
viability, confirming the strong growth inhibitory effect of ESRP2 in luminal BC cells. 
T47D-ESRP-KO cells showed mild reduction of viability compared to T47D-Cas9 control 
cells, and T47D-ESRP DKO-RBMS3 cells showed significantly increased cell growth 
compared to T47D-ESRP DKO cells, suggesting that RBMS3 promotes cell growth under 
depletion of both ESRPs (Figure 4.48). Based on cell migration assay, ESRP1 significantly 
suppressed MCF7 and T47D cell migration. ESRP2, however, appeared to promote MCF7, 
but not T47D, cell migration. Loss of both ESRPs significantly promoted T47D, but not 
MCF7, cell migration compared to control. As expected, RBMS3 induced migration of 
T47D and MCF7 cells with loss of both ESRPs (Figure 4.49). Scratch assay suggested that 
cells with RBMS3 or loss of ESRP1 had faster wound closure rate, further confirming the 
migration suppressive role of ESRP1 in both cell lines. Loss of ESRP2 led to slower closure 
in MCF7, but not in T47D cells, which is consistent with results of migration assay (Figure 
4.50).  Compared to Cas9 control cells, loss of ESRP1 greatly facilitated colony formation, 
whereas loss of ESRP2 inhibited colony formation. Surprisingly, fewer colonies were 
formed when both ESRPs are lost, this may be due to the contradictory roles of ESRP1 and 
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ESRP2 on colony formation (Figure 4.51). Mammosphere assay showed that cells with 
loss of ESRPs, especially ESRP2, formed irregular mammospheres, unlike the rounded 
ones formed by control cells. In addition, loss of ESRP1 or ESRP2 affected formation of 
large mammospheres, but not small mammospheres (Figure 4.52-53). When grown in 3D 
Matrigel, expression of RBMS3 or loss of ESRPs promoted formation of small 
mammospheres in T47D cells. Conversely, loss of either ESRP1 or ESRP2 showed little 
effect on mammosphere formation compared with control (Figure 4.54).  When cells were 
cultured in round-bottomed low-attach 96-well plates, we noticed that RBMS3 or loss of 
ESRP2 appears to promote cell dispersion (Figure 4.55). Collectively, our results indicate 
that ESRP1, ESRP2 and RBMS3 play distinct roles in BC: While ESRP1 primarily inhibits 
migration, ESRP2 mainly suppresses proliferation and promotes migration. The opposite 
functions of ESRP1 and ESRP2 on cell migration may be explained by the requirement of 
mammary branching morphogenesis during development, possibly controlled by the 
relative endogenous levels of these two proteins.  
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Figure 4.48 ESRP1, ESRP2 and RBMS3 play distinct roles on cell viability 
103 cells were seeded in 100 µL medium and cultured for indicated time. 50 µL medium 
was removed and 50 µL Cell-Glo Titer 2.0 reagent added to each well before testing. Plates 
were shaken 5 minutes and stabilized for another 5 minutes. All values were normalized to 
MCF7 or T47D cells. Data are shown as mean ± SD from two independent experiments. 
All values are compared to Cas9 control except that RBMS3-OE is compared to wild-type 
control. In the MCF7-derived cell lines, p<0.05 (ESRP DKO vs. Control), p<0.01 (ESRP 
DKO-RBMS3 vs. Cas9), p<0.001 (ESRP2 vs. Cas9), NS (RBMS3 vs. Control, ESRP1 KO 
vs. Cas9). In the T47D-derived cell lines, p<0.05 (ESRP1 KO vs. Cas9, ESRP DKO vs. 
Cas9), p<0.001 (ESRP2 vs. Cas9), NS (RBMS3 vs. Control, ESRP DKO vs. Cas9) 
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Figure 4.49 ESRP1, ESRP2 and RBMS3 play distinct roles on cell migration 
5.0 x104 cells were seeded on top of the Matrigel in the upper Boyden chamber and the 
bottom chamber was filled with culture medium containing EGF (10 ng/mL) as the 
chemoattractant. After 48 hours, the underside of the Boyden chamber membrane was 
fixed, stained and counted. Data are shown as mean ± SD from three independent 
experiments. All values are compared to wild-type control. (*p < 0.05, **p < 0.01, *** < 
0.001) 
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Figure 4.50 ESRP1, ESRP2 and RBMS3 play distinct roles on wound healing 
MCF7-derived (A) and T47D-derived (B) cells were grown to around 90% confluency and 
serum-starved overnight. A scratch (‘wound’) was inflicted to the cell layer. Wound 
closure was photographed at 0 and 24 hour. Cell migration rate was calculated upon the 
difference of gap width at 24 hour compared to 0 hour depending on the speed of wound 
closure. Data are shown as mean ± SD from two independent experiments. All values are 
compared to wild-type control. 
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Figure 4.51 ESRP1, ESRP2 and RBMS3 have distinct roles on colony formation 
103 cells were seeded in the upper layer of the soft agar plate and grown for two weeks. 
Colonies were stained with crystal violet and counted under four random views. Data are 
shown as mean ± SD from three independent experiments. (**p < 0.01) 
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Figure 4.52 ESRP1, ESRP2 and RBMS3 have distinct effects on mammosphere 
formation 
Tumorsphere formation was assessed in MCF7 cell with or without loss of ESRPs and in 
the presence or absence of RBMS3. 105 cells were seeded in 6-well plate using commercial 
mammosphere-forming media and cultured for two weeks. Representative images of seven 
MCF7-derived cell lines are shown. Scale bars, 1000 µm.  
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Figure 4.53 RBMS3 or loss of ESRPs inhibits mammosphere formation 
Graphic representation of tumorsphere counts based on tumorsphere size (30 µm) in 
MCF7-derived cell lines from tumorsphere formation assay. Data are shown as mean ± SD 
from twenty independent views. 
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Figure 4.54 RBMS3, or loss of ESRPs, promotes formation of small tumorsphere 
clusters 
Representative images of 3D on-top Matrigel culture in MCF7-derived cell lines.1.5x 104 
cells were seeded on a layer of Matrigel and 10% Matrigel was covered on top. Cells were 
culture and photographed at day 4. 
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Figure 4.55 Representative images of adhesion-independent growth of luminal BC 
cells with or without ESRPs and/or RBMS3 
Adhesion-independent growth of 14 luminal BC-derived clones were examined. Briefly, 
0.8x103 cells were seeded in 96-well round bottom ultralow-attachment plates. Cells were 
cultured for up to one week and photographs were taken daily. Shown are representative 
images of day 1 and day 7. All cells are seeded in triplicates. 
4.11 Identification of Alternative Splicing Events Regulated by ESRPs and RBMS3 
While much is known about transcriptional regulation of EMT, alternative splicing 
of genes and their contributions to the morphological conversion accompanying EMT have 
not been comprehensively investigated. Although ESRP1 and ESRP2 have been shown to 
inhibit AS events during EMT, it remains unclear whether RBMS3 also alter splicing of 
genes and if these three RBPs share common targets that are directly involved in EMT. To 
dissect the mechanism by which ESRP1, ESRP2 and RBMS3 regulate EMT, we used the 
established cell culture model and RNA-seq analysis to assess changes in transcriptional 
programs. Briefly, as mentioned above, we knocked out each or both of the ESRP1 and 
ESRP2, or overexpressed RBMS3 in T47D cells. A total of seven clones (T47D, T47D-
Cas9, T47D-RBMS3, T47D-ESRP1 KO, T47D-ESRP2 KO, T47D-ESRP DKO and T47D-
ESRP DKO-RBMS3) were sent for RNA-seq. To deduce regulon of the three RBPs from 
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our dataset, we paired matched the expression results of each clone to generate lists of 
DEGs (marked as A, B, C, D, E, and F) potentially regulated by the corresponding RBP 
(Figure 4.56). By cross-checking each list, information of potential regulon was obtained. 
Depletion of ESRPs affected expression of 4705 transcripts, 49.3% of which were 
downregulated, whereas overexpression of RBMS3 affected a smaller set of 1307 
transcripts, 61% of which were upregulated (Figure 4.57A). Interestingly, by comparing 
lists B and C, significantly less transcripts were affected by RBMS3 when ESRPs were 
already depleted, revealing similar regulatory functions for these RBPs. Comparison of 
lists E and F showed that the number of genes regulated by ESRPs and RBMS3 is more in 
‘EMT’ than in ‘MET’ process (Figure 4.57B). Among the 71 and 2096 consistently 
regulated transcripts, only 14 were potentially shared by ESRP(s) and RBMS3 (Figure 
4.57C). A heatmap of the top 60 DEGs is shown for RBMS3 and ESRP depletion lists 
(Figure 4.57D). 
We also performed AS analysis in RNA-seq data using R software to individually 
quantify and analyze differences in AS events. The number of top AS events were listed 
and compared. Among all AS events, 39 events were shared by ESRP1 and ESRP2. 
Another 39 events were shared by ESRP1 and RBMS3; and 53 were shared by ESRP2 and 
RBMS3. Interestingly, one event was found to be commonly regulated by all three RBPs 
(Figure 4.58A). Next, we examined five common types of alternative isoform expression 
events, each capable of producing multiple mRNA isoforms from a gene through AS. 
These AS events included 3’ alternative splicing (A3SS), 5’ alternative splicing (A5SS), 
exon skipping (SE), retained intron (RI) and mutually exclusive exon (MXE). A 
comprehensive set of 9808 events of these five types was derived from the analysis in 
T47D-RBMS3 versus control cells. 9461 and 9874 events were observed in T47D-ESRP1 
KO and T47D-ESRP2 KO versus control cells, respectively. These events were then 
ranked to generate top splicing lists based on reads. As observed for transcriptional targets, 
the overlap between alternatively spliced exons regulated by these RBPs was moderate.  In 
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T47D-RBMS3 versus control T47D cells, MXE event occurs most frequently in the top 
splicing list. A3SS and A5SS events occur at similar moderate levels, whereas RI event 
appears least frequently (Figure 4.58B).  
 
 
 
Figure 4.56 Schematic of analytic workflow of RNA-seq dataset 
Expression sets of these four cell lines were pair-matched and compared by FC, generating 
lists of DEGs marked as group A, B, C, D, E and F.  FC greater than 0.5 is considered as 
differentially expressed. By cross-checking each list, information on the potential regulon 
of each RBP will be inferred.  
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Figure 4.57 Expression Regulation by ESRP1, ESRP2 and RBMS3 
(A) Number and percentage of transcripts up- or downregulated more than 1.5 fold upon 
depletion/overexpression of the indicated RBPs. 
(B) Number of DEGs (>1.5 fold) present in each list. 
(C) Number DEGs consistently present or consistently regulated in both list B and C, or A 
and D. Circles represent the number of DEGs regulated by the indicated RBPs. Overlap 
between gene expression changes is shown in blue. 
(D) Heatmap for the top 60 DEGs in RNA-seq dataset. 
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Figure 4.58 Splicing Regulation by ESRP1, ESRP2 and RBMS3 
(A) Overlap between alternative splicing changes observed upon RBP depletion or 
overexpression. 
(B) Number of splicing changes upon depletion of the RBPs across categories of alternative 
splicing events. A3SS = 3’ alternative splice site, A5SS = 5’ alternative splice site, SE = 
exon skipping, RI = retained intron, MXE = mutually exclusive exon 
4.12 Proposed Model of ESRPs and RBMS3 in BC 
Normal mammary cells express potent epithelial regulators, such as ESRPs, to 
govern epithelial identity and suppress EMT. In normal ductal cells and luminal BC cells, 
TGF-βr signaling remains at minimal/undetected level. Upon stimulation by external TGF-
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β, cells respond through an intricate balance of Smad-dependent or independent signaling, 
eventually driving the tumor-supressing arm of TGF-βr signaling. During advanced BC 
stages, chronic activation of high levels of TGF-βr signaling disables/inactivates the tumor-
suppresing arm, which shifts the equilibrium to the tumor-promoting arm and leads to 
activation of oncogenes like RBMS3. RBMS3 upregulates Smad proteins and further 
enhances TGF-βr signaling, which induces expression of EMT master regulators, 
eventually leading to metastatic behaviors of cancer cells, characterized by loss of 
epithelial polarity and conversion into an elongated, migratory and invasive phenotype 
(Figure 4.59) [55].   
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Figure 4.59 Proposed model on RBMS3 and ESRPs 
Mammary ductal cells possess intrinsic apical-basal epithelial polarity maintained by 
several types of cellular junctions. TGF-β signaling is initiated by ligand-induced 
oligomerization of serine/threonine receptor kinases and phosphorylation of the 
cytoplasmic molecules Smad2/3, resulting in their interactions with transducer Smad4 and 
translocation into the nucleus. Activated Smads regulate diverse biological effects by 
partnering with other transcription factors, leading to cell-state specific modulation of 
transcription. Specifically, in premalignant cells, cell cycle arrest and apoptosis are two 
common pathways that are regulated by TGF-β signaling to suppress tumor formation. On 
the contrary, during later stage of tumorigenesis, the tumor suppressing arm of TGF-β is 
disabled, shifting to tumor-promoting arm of TGF-β signaling, leading to activation of 
oncogenes like RBMS3. RBMS3 upregulates TGF-β-regulated EMT master regulators 
(Snail, Slug and Twist, etc) and promote tumor progression by transcriptional control of 
EMT genes, eventually resulting in tumor progression. (Orange shape indicates ligand; 
Blue and purple hooked shapes indicate serine/threonine receptor kinases; Beige egged 
shape with black outline indicates nucleus; Black turning arrow indicate ‘activation of 
transcription’; Double wave indicates DNA; Single wave indicates RNA) 
 
 
CHAPTER 5. DISCUSSION 
For the past decade, increasing attention has been drawn to the post-
transcriptional network of EMT, which involves alternative splicing, noncoding RNA 
and mRNA stability, etc. RBMS3 is a possible post-transcriptional regulator that popped 
out from our microarray dataset. So far the function of RBMS3 in tumorigenesis has 
been seemingly controversial. Despite being downregulated in TCGA overall breast 
tumor patients compared to normal counterparts, RBMS3 shows increased expression 
among invasive BLBC cells. Hence, it may be difficult to interpret the actual function 
of RBMS3 solely based on TCGA data due to heterogeneous nature of breast tumors. 
Intriguingly, Oncomine dataset also showed that RBMS3 is highly expressed in the 
immune cells, which indicated RBMS3 could potentially play a role in the immune 
system (data not shown). Another interesting conundrum is that, while the expression of 
both ESRPs are low in normal epithelium, they are upregulated in luminal BC cells and 
downregulated in invasive fronts. 
In an attempt to study RBMS3 and ESRPs in detail, we took the advantage of 
several BLBC cell lines and luminal BC cell lines. These two subtypes of BC cells are 
commonly used to study the EMT process as they nicely represent the epithelial state 
and mesenchymal state, respectively. As luminal BC cells and basal-like BC cells arise 
from genetically-different backgrounds, we were not unexpected to see inconsistencies 
on the viability assay between MCF7 cell and BT-549 cells. Failure to elicit effect on 
proliferation in MCF7 cells does not imply that RBMS3 cannot not involved in cell 
proliferation, as its effect could neutralized or mitigated by other potent factors in the 
MCF7 cells. Surprisingly, unlike previous studies that revealed largely redundant roles 
for ESRP1/2 on cell motility in several cancers [153-155], we observed differential 
functions of ESRP1/2 on luminal BC cell migration and proliferation. While ESRP1/2 
are essential to suppress EMT, loss of ESRPs is not sufficient to drive mesenchymal 
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phenotype in luminal BC cells, suggesting that other core molecules may be involved in 
the EMT process. Our functional assays revealed that RBMS3 has important roles on 
cell migration, invasion and CSC self-renewal. Specifically, CSCs are thought to be 
responsible for drug resistance and disease relapse, and the rationale behind 
mammosphere assay is that only CSCs are able to form individual mammospheres in the 
specialized medium under suspension condition. Compared to the control cells that 
formed regular-sized and sphere-shaped mamospheres, RBMS3 overexpression led to 
significantly increased numbers of small and irregular-shaped clusters which tend to be 
quite loose and unstable, reminiscent of what is observed in the MCF7 cells with 
knockdown of E-cadherin. Indeed, formation of small and loose cell cluster appears to 
be more favorable for cancer cell dissemination in the circulation as it may increase the 
efficiency of spreading and the chances of forming metastasis.  
To study whether RBMS3 serves as a central player in the EMT process, we 
induced RBMS3 expression in T47D and MCF7 luminal BC cells as well as in those 
with loss of both ESRPs. T47D and MCF7 cells are widely studied in breast cancer 
mechanisms. While both being estrogen receptor-positive, they have intrinsically 
distinct genetic background and molecular profiles as previous studies from 2D gel and 
mass spectrometry have revealed that several proteins involved in cell growth 
stimulation and anti-apoptotic mechanisms are more strongly expressed in T47D than 
MCF7 cells. Additionally, MCF7 cells are reported TP53 wildtype, while T47D cells 
are TP53 mutant. These reasons may be at least partially responsible for the 
inconsistencies between MCF7- and T47D-derived cell lines observed in our functional 
assays. Specifically, since T47D-ESRP DKO and T47D-ESRP DKO-RBMS3 cells grew 
in clusters and attached loosely to culture dish, it may be possible that a small portion 
of the cells were lost at medium removal step during cell viability assay, affecting the 
final measurement and leading to lower values. Unfortunately, we failed to observe 
notable morphological or molecular changes to mesenchymal phenotype. However, 
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upon overexpression of EMT transcription factor Slug, we observed that T47D-ESRP 
DKO-RBMS3 cells transformed into a typical mesenchymal morphology, characterized 
by spindle-like shape, at a much faster rate than that of the T47D-ESRP DKO cells, 
indicating that T47D-ESRP DKO-RBMS3 cells reside in a place that is closer to the 
mesenchymal state than the T47D-ESRP DKO cells. These data also inform us that other 
essential factors may also be engaged in the EMT process. To elucidate this, co-
immunoprecipitation of RBMS3 followed by liquid chromatography-mass spectrometry 
(LC-MS) may be performed to identify potential RBMS3-interacting partners. 
Alternatively, we may perform stable isotope labeling by essential nutrients in cell 
culture (SILEC) for LC-MS analysis. Furthermore, loss of both ESRPs conquered the 
apoptotic effect induced by long term expression of EMT transcription factors, 
suggesting that ESRPs may be responsible in regulating apoptotic pathways that are 
suppressed in mesenchymal cells. 
To date, the mechanistic role of RBMS3 in human development has not been 
established. The one and only study for in vivo function of RBMS3 was described in the 
zebrafish model, where RBMS3 is transiently expressed in the cytoplasm of migrating 
cranial neural crest (CNC) in the pharyngeal arches during cartilage differentiation. 
RBMS3 spatiotemporally controls the timing and duration of the TGF-βr signaling 
within CNC cells through transcript stability of TGF-βr pathway components, which 
influences proliferation and initial differentiation of prechondrogenic CNC. TGF-βr 
pathway promotes Sox9-dependent transcriptional activity on the a1 (II) collagen gene 
(COL2A1) enhancer to induce chondrogenesis [156]. That being said, a certain threshold 
of TGF- βr signaling is likely to be required to drive prechondrogeneic cells down the 
cartilage lineage.  Once become committed to chondrogenesis, Rbms3 expression is shut 
down in these cells [136]. For years TGF-β, a potent pleiotropic cytokine, has been 
known as an inducer of cell arrest in benign cells and early-stage tumors, but also a 
contributor of breast cancer cellular heterogeneity and metastasis. This mysterious 
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phenomenon or conundrum is considered as the ‘TGF-β’ paradox. Unfortunately, due to 
the dual nature of TGF-β in BC patients, it is unlikely to be utilized as a tumor marker 
to distinguish patients with high risk of metastasis [157]. To date, regulators involved 
in TGF-β signaling during tumor progression and the underlying mechanisms still 
remain to be clarified. Despite of difficulty, increasing evidence has revealed that the 
diversity of TGF-β response is determined by combinatorial usage of core pathway 
components [158]. Therefore, unraveling the activities of these central players is crucial 
to understand the execution of TGF-β-mediated EMT. It is known that expression of E-
cadherin is suppressed by Snail [47], which is shown in this study to be induced by 
RBMS3-mediated TGF-β/Smad signaling.  
We based our study on the finding in the zebrafish model. In our studies, we 
verified the link between TGF-β and RBMS3 in breast cancer cells and provided detailed 
mechanisms for RBMS3-mediated activation of TGF-β/Smad signaling. Our findings on 
RBMS3 have at least four broader impacts: 1) It furthers our understanding of TGF-β 
pathway; 2) It enables the possibility of using RBMS3, instead of TGF-β, as a potential 
tumor marker to distinguish patients with higher probability of metastasis; 3) It 
facilitates the discovery of other essential mRNA regulators important for EMT; 4) 
Understanding the importance of RBMS3 help us to further study the role of RBMS3 in 
human development and other biological processes. 
In bone-metastatic cancer cells, connective tissue growth factor (CTGF) is highly 
expressed and secreted [159]. CTGF is known to be expressed at low levels in luminal 
BC cells and found to mediate TGG-β-induced apoptosis in MCF7 cells. Interestingly, 
we found significant downregulation of CTGF in luminal BC cells with expression of 
RBMS3, suggesting that even though RBMS3 may conquer TGF-β-mediated apoptosis 
and cytostasis, its expression alone failed to elicit TGF-β-mediated metastasis in luminal 
BC cells. We also noticed that depletion of RBMS3 downregulated Smad2 and Smad3 
but not Smad4. This suggest that RBMS3 tightly controls the total pool of Smad2 and 
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Smad3 through regulating mRNA stability. The inconsistency between qPCR and Act D 
stability assay, reflected by unaffected level of Smad4 mRNA and decreased Smad4 
mRNA stability in BT-549 RBMS3-KO compared to control cells, suggest that Smad 
may also be regulated through other post-transcriptional or translational mechanisms. 
Interesting, when we induce BT549 control and RBMS3-KO cells with TGF-β1, we 
observed downregulation of Slug and Twist and upregulation of Snail in BT549 cells 
that is absent in the RBMS3-KO cells, suggesting a possible feedback loop for the cells 
to maintain the equilibrium of EMT genes.  
Using Kaplan-Meier Plotter, we discovered a correlation between RBMS3 
expression and prognosis in BC. The prognosis of advance stage BC patients with high 
expression RBMS3 was poor compared with those with low expression of RBMS3. Here 
we demonstrated that RBMS3 is closely associated with BC malignancy, suggesting 
RBMS3 may serve as a novel prognostic marker and therapeutic target for malignant 
BC. Beyond our study is whether RBMS3 exert the same tumor-promoting roles in vivo. 
As for future directions, in vivo studies should be performed to find out whether RBMS3 
is critical for tumorigenicity of TNBC and whether RBMS3 inhibitors may suppress the 
tumorigenicity by inhibiting TGF-β pathway.  
From our RNA-seq analysis, we discovered several expression events that are 
potentially co-regulated by ESRP1, ESRP2 and RBMS3. However, whether these DEGs 
are direct targets or consequence of ‘butterfly effect’ is still unknown. Additionally, we 
also identified several promising AS events. These targets should be validated in order 
to identify critical ones that are indispensable and consistently changed during the EMT 
process. The study of these DEGs will greatly enhance our understanding of the post -
transcriptional network and landscape of EMT and metastasis. Additionally, we 
identified one AS event co-regulated by ESRPs and RBMS3. This AS event was 
unpublished and leads to the production of two isoforms of the gene product, which is a 
membrane protein that has at least 2-3 isoforms. One isoform was reported to be closely 
120 
 
related to mammary tumors. Therefore, it will be interesting to study whether ESRPs 
and RBMS3 truly regulate the splicing of this gene and how this process contributes to 
EMT. 
The characterization of RBMS3 expression in BC during my dissertation 
research, including the phenotypic and mechanistic data, answered several questions 
about the tumor promoter role of RBMS3. However these data have also raised several 
more important pertinent questions. As for further directions, firstly, it may be necessary 
to study the biological function of RBMS3 in greater detail. While RBMS3 has been 
shown to reduce cell contact and E-cadherin, it will be interesting to study how RBMS3 
regulates polarity. In addition, since RBMS3 belongs to the MSSP family and other 
members are found to be involved in gene transcription, cell cycle and apoptosis, we 
anticipate that the role of RBMS3 on TGF-β-mediated cytostasis and apoptosis is 
mediated through transcriptional regulation of c-myc. Secondly, the study of splicing 
mechanisms of ESRPs and RBMS3 will provide detailed information on the post-
transcriptional landscape of EMT. Thirdly, according to TCGA data on Oncomine 
website, RBMS3 shows a differential expression pattern in immune cells of breast 
carcinoma. Fourthly, a published microarray indicated that knockdown of ER induced 
expression of RBMS3, suggesting a potential positive correlation on the hormonal 
control of RBMS3. Oppositely, we expect that RBMS3 expression will lead to reduction 
of ER, leading to the ER-negative phenotype. Fifthly, due to the predominant presence 
of RBMS3 in the cytoplasm, it might be involved in other aspects of the RNA 
metabolism, such as RNA localization, mRNA decay, translational regulation, etc. 
Lastly, the role of RBMS3 in cancer has been controversial. A number of studies have 
shown as RBMS3 as a tumor suppressor in pancreatic cancer, epithelial ovarian cancer 
and epithelial esophageal carcinoma. However, results from our study have provided 
opposite lines of evidence for RBMS3, resulting in the conflict within the field. 
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Therefore, it will be necessary to address the in vivo function of RBMS3 in BC by IHC 
analysis and mouse studies. 
Beyond this study are some bigger questions that are waiting for answers. Firstly, 
it is still unclear whether cells at the invasive front are predetermined to serve a leader role 
or are simply induced to a leader phenotype due to their close interactions with the 
environment. Is RBMS3 expressed only in the leader cells? When do cells begin to express 
RBMS3? Is RBMS3 silenced during mesenchymal-epithelial transition (MET) process 
after seeding metastasis? How is RBMS3 regulated by the spatiotemporal control of cell 
signals? In order to find out the answers, it may be necessary to investigate the micro-
environmental context in greater details. Secondly, the on-off switch that drives the 
expression of RBMS3, which subsequently triggers TGF-β to work as a tumor promoter 
during metastasis, is still unknown. Lastly, the mechanism underlying the transition of 
collective movement into widespread dissemination in the metastatic cascade also remains 
an open question. 
In summary, the study within this dissertation has uncovered a pivotal role of 
RBMS3 in maintaining mesenchymal identity and promoting EMT in BC. This study 
allows us to explore the potential of using RBMS3 as a classification marker to stratify 
high grade tumors with high levels of TGF-β signaling and a diagnostic marker for 
developing TNBC treatment strategies. It also provides directions on the identification of 
RBMS3-regulated DEGs or splicing patterns that may also serve as diagnostic markers. 
These studies will greatly enhance our understanding of the post-transcriptional regulation 
of EMT and breast cancer progression. 
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Table 5 EMT and apoptosis status in T47D-derived cells with overexpression of 
Slug/Snail/Twist or TGF-β treatment (10 ng/mL) at day 9 (post transfection or 
treatment). 
Cell Lines Slug Snail Twist TGF-β 
EMT Apoptosis EMT Apoptosis EMT Apoptosis EMT Apoptosis 
Control - +++ - +++ - + - +++ 
RBMS3 - + - + - - - + 
ESRP1 KO - + - + - + - - 
ESRP2 KO - + - + - - - - 
ESRP DKO - - - - - - - - 
ESRP DKO-
RBMS3 
++ - ++ - - - + - 
*The number of ‘+’ represents the degree or extent of apoptosis, which is measured by the 
number of viable cells. Note that we summarize ‘EMT’ status only based on typical 
spindle-like appearance instead of other characteristics or phenotypes.
 
 
 
APPENDIX 
List of Acronyms and Abbreviations 
Abbreviation Acronym 
ANK Ankyrin repeats 
ARE AT-rich element 
AUF1 AU-rich element RNA binding protein 1 
BLBC Basal-like breast cancer 
CCLE Cancer cell line encyclopedia 
Co-Smad Co-regulatory Smad 
CSC Cancer stem cell 
CTBP C-terminal-binding protein 
CTGF Connective tissue growth factor 
DEG Differentially expressed genes 
DMEM Dulbecco’s Modified Eagle Medium 
E-cad E-cadherin 
ELAV Embryonic lethal abnormal vision 
EMT Epithelial-Mesenchymal Transition 
ER Estrogen receptor 
ESRP Epithelial splicing regulatory protein 
FACS Fluorescent Activated Cell Sorting  
FBS Fetal Bovine Serum 
FC Fold change 
FGFR Fibroblast growth factor receptor 
GO Gene ontology 
HEPES Hydroxyethyl piperazineethanesulfonic acid  
HER2 Human epidermal receptor 2 
HMGA2 High mobility group AT-Hook 2 
hTERT Human telomerase reverse transcriptase 
IHC immunohistochemistry 
JAK Janus kinase 
JNK c-Jun N-terminal kinase 
KC Chemokine ligand 1 
KEGG Kyoto Encyclopedia of Genes and Genomes 
KO Knockout (of a gene) 
LC-MS liquid chromatography-mass spectrometry 
MAPK Mitogen-activated protein kinase 
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MAPKKK Mitogen-activated protein kinase kinase kinase 
MaSC Mammary stem cell 
MCODE Molecular Complex Detection 
MET Mesenchymal-Epithelial Transition 
N/A Not applicable 
NICD Notch intracellular fragment 
NLS Nuclear localization signal 
OE Overexpression 
ORF Open reading frame 
PARP poly(ADP-ribose) polymerase 
PD-L1 Programmed death ligand 1 
PEST Proline (P), glutamic acid (E), serine (S) and threonine (T) 
PKC Protein kinase C 
PR Progesterone receptor 
qPCR Quantitative Real-time Polymerase Chain Reaction 
RAM RBPJ-κ association module 
RBD RNA binding domain 
RBMS3 RNA binding motif single-stranded protein 3 
RBP RNA binding protein 
RBPJ Recombination Signal Binding Protein For Immunoglobulin 
Kappa J Region 
RRM RNA recognition motif 
SILEC Stable Isotope Labeling by Essential nutrients in Cell culture 
SMAD Homologies to the Caenorhabditis elegans SMA (‘small’ 
worm phenotype) and Drosophila MAD (‘Mother Against 
Decapentaplegic’) family of genes 
R-Smad Regulatory Smad 
RTK Receptor tyrosine kinase 
Ser-Thr Serine and threonine 
SFRP1 Secreted frizzled related protein 1 
snRNP Small nuclear ribonucleoprotein  
TAD Transcriptional activation domain 
TAK1 Transforming growth factor β-activated kinase 1 
TIL Tumor-infiltrating lymphocytes 
TβR TGF-β receptor 
TGF-β Transforming growth factor beta 
TNBC Triple-negative breast cancer 
TPM Transcript per million 
TRIM Tripartite motif containing 
TTP Tristetraprolin 
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VEGF Vascular endothelial growth factor 
UTR Untranslated region 
ZEB1 Zinc finger E-box binding homeobox 1 
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